Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
J Crohns Colitis
    April 2024
  1. BURTON-MURRAY H, Kiser K, Gurung J, Williams K, et al
    Avoidant/restrictive food intake disorder symptoms are not as frequent as other eating disorder symptoms when ulcerative colitis is in remission.
    J Crohns Colitis. 2024 Apr 18:jjae052. doi: 10.1093.
    >> Share

  2. BROWN M, Dodd A, Shi F, Greenwood E, et al
    Concordant B and T Cell Heterogeneity Inferred from the Multiomic Landscape of Peripheral Blood Mononuclear Cells in a Crohn's Disease Cohort.
    J Crohns Colitis. 2024 Apr 13:jjae055. doi: 10.1093.
    >> Share

  3. PETIT P, Leroyer A, Chamot S, Fumery M, et al
    Farming activities and risk of inflammatory bowel disease: a French nationwide population-based cohort study.
    J Crohns Colitis. 2024 Apr 12:jjae050. doi: 10.1093.
    >> Share

  4. MOHAMEDRASHED M, Garg M, Bohra A
    Advocating for Consensus: The crucial role of standardised Magnetic resonance imaging (MRE) protocols and image quality metrics in assessment of Crohn's disease.
    J Crohns Colitis. 2024 Apr 12:jjae051. doi: 10.1093.
    >> Share

  5. TIONG HT, Fan D, Frampton C, Ananthakrishnan AN, et al
    Physical Activity Is Associated With A Decreased Risk Of Developing Inflammatory Bowel Disease: A Systematic Review And Meta-Analysis.
    J Crohns Colitis. 2024 Apr 10:jjae053. doi: 10.1093.
    >> Share

  6. ZADORA W, Innocenti T, Verstockt B, Meijers B, et al
    Chronic kidney disease in inflammatory bowel disease, a systematic review and meta-analysis.
    J Crohns Colitis. 2024 Apr 8:jjae049. doi: 10.1093.
    >> Share

  7. MERTZ NORGARD B, Garvik OS, Zegers FD, Nielsen J, et al
    New surgery and hospital-diagnosed infections in elderly patients with inflammatory bowel disease undergoing surgery - a nationwide cohort study.
    J Crohns Colitis. 2024 Apr 5:jjae047. doi: 10.1093.
    >> Share

  8. VAN LINGEN E, Nooij S, Terveer E, Crossette E, et al
    Fecal Microbiota Transplantation engraftment after budesonide or placebo in patients with active ulcerative colitis using pre-selected donors: a randomized pilot study.
    J Crohns Colitis. 2024 Apr 4:jjae043. doi: 10.1093.
    >> Share

    March 2024
  9. KUMAR S, De Kock I, Blad W, Hare R, et al
    Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn's disease.
    J Crohns Colitis. 2024 Mar 30:jjae042. doi: 10.1093.
    >> Share

  10. VAN DEN HOUTE M, Guadagnoli L, Ohman L, Bergstedt A, et al
    Predictors of symptom trajectory in newly diagnosed ulcerative colitis: a 3-year follow-up cohort study.
    J Crohns Colitis. 2024 Mar 29:jjae046. doi: 10.1093.
    >> Share

  11. CUNHA MF, Roseira J
    Letter to the Editor regarding the article Minimally invasive surgery for Inflammatory Bowel Disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques.
    J Crohns Colitis. 2024 Mar 28:jjae045. doi: 10.1093.
    >> Share

  12. SCIBERRAS M, Farrugia Y, Gordon H, Furfaro F, et al
    Accuracy of Information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO Guidelines.
    J Crohns Colitis. 2024 Mar 23:jjae040. doi: 10.1093.
    >> Share

  13. SHRESTHA S, Brand JS, Osooli M, Eriksson C, et al
    Spondyloarthritis in first-degree relatives and spouses of patients with inflammatory bowel disease: A nationwide population-based cohort study from Sweden.
    J Crohns Colitis. 2024 Mar 22:jjae041. doi: 10.1093.
    >> Share


  14. Corrigendum to: Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Mar 20:jjae021. doi: 10.1093.
    >> Share

  15. VAN GENNEP S, Fung ICN, de Jong DC, Ramkisoen RK, et al
    Histological Outcomes And Jak-Stat Signalling In Ulcerative Colitis Patients Treated With Tofacitinib.
    J Crohns Colitis. 2024 Mar 20:jjae031. doi: 10.1093.
    >> Share

  16. CON D, Hilley P, Chin S, Corte C, et al
    Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation.
    J Crohns Colitis. 2024 Mar 19:jjae039. doi: 10.1093.
    >> Share

  17. FUNG M, Farbod Y, Kankouni H, Singh S, et al
    Does combined medical and surgical treatment improve perianal fistula outcomes in patients with Crohn's disease? A systematic review and meta-analysis.
    J Crohns Colitis. 2024 Mar 16:jjae035. doi: 10.1093.
    >> Share

  18. GENG Z, Li J, Zuo L, Zhang X, et al
    Intestinal adipocytes transdifferentiate into myofibroblast-like cells and contribute to fibrosis in Crohn's disease.
    J Crohns Colitis. 2024 Mar 11:jjae036. doi: 10.1093.
    >> Share

  19. ZAMAN S, Mohamedahmed AYY, Abdelrahman W, Abdalla HE, et al
    Minimally invasive surgery for Inflammatory Bowel Disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques.
    J Crohns Colitis. 2024 Mar 11:jjae037. doi: 10.1093.
    >> Share

  20. LEHMANN M, Weixler B, Elezkurtaj S, Loddenkemper C, et al
    Spatial single cell profiling using imaging mass cytometry - inflammatory versus penetrating Crohn's disease.
    J Crohns Colitis. 2024 Mar 11:jjae033. doi: 10.1093.
    >> Share

  21. ELLRICHMANN M, Schulte B, Conrad CC, Schoch S, et al
    Contrast enhanced endoscopic ultrasound detects early therapy response following anti-TNF-therapy in patients with ulcerative colitis.
    J Crohns Colitis. 2024 Mar 8:jjae034. doi: 10.1093.
    >> Share

  22. TEUGELS A, van den Eijnden I, Keersmaekers B, Verstockt B, et al
    Disease acceptance, but not perceived control, is uniquely associated with inflammatory bowel disease-related disability.
    J Crohns Colitis. 2024 Mar 6:jjae025. doi: 10.1093.
    >> Share

  23. BIEL C, Faber KN, Bank RA, Olinga P, et al
    Matrix metalloproteinases in intestinal fibrosis.
    J Crohns Colitis. 2024;18:462-478.
    >> Share

  24. WARSOP ZI, Manzo CA, Yu N, Yusuf B, et al
    Patient-reported Outcome Measures in Ileoanal Pouch Surgery: a Systematic Review.
    J Crohns Colitis. 2024;18:479-487.
    >> Share

  25. JOJART B, Resal T, Kata D, Molnar T, et al
    Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18:392-405.
    >> Share

  26. WEBER S, Sitte S, Voegele AL, Sologub L, et al
    NLRP3 Inhibition Leads to Impaired Mucosal Fibroblast Function in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18:446-461.
    >> Share

    February 2024
  27. ROSH JR, Turner D, Hyams JS, Dubinsky M, et al
    Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease.
    J Crohns Colitis. 2024 Feb 26:jjae030. doi: 10.1093.
    >> Share

  28. TORRES J, Colombel JF, Mary JY
    Lemman Index in Children: Still an Open Question.
    J Crohns Colitis. 2024;18:331-332.
    >> Share

  29. GEBEYEHU GG, Taylor F, Dobson L, Cummings JRF, et al
    Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic survey.
    J Crohns Colitis. 2024;18:275-285.
    >> Share

  30. GRANT RK, Jones GR, Plevris N, Lynch RW, et al
    Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset.
    J Crohns Colitis. 2024;18:286-290.
    >> Share

  31. DHALIWAL J, Tertigas D, Carman N, Lawrence S, et al
    Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
    J Crohns Colitis. 2024;18:233-245.
    >> Share

  32. LO B, Biederman L, Rogler G, Dora B, et al
    Specific antibiotics increases the risk of flare-ups in patients with inflammatory bowel disease - results from a Danish nationwide population-based nested case-control study.
    J Crohns Colitis. 2024 Feb 17:jjae027. doi: 10.1093.
    >> Share

  33. ARJOMAND FARD N, Wine E
    Clostridium perfringens: A Potential Pathobiont in Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Feb 16:jjae019. doi: 10.1093.
    >> Share

  34. KOELINK PJ, Gomez-Mellado VE, Duijst S, van Roest M, et al
    The phospholipid flippase ATP8B1 is involved in the pathogenesis of Ulcerative Colitis via establishment of intestinal barrier function.
    J Crohns Colitis. 2024 Feb 16:jjae024. doi: 10.1093.
    >> Share

  35. REINISCH W, Colombel JF, D'Haens GR, Rimola J, et al
    Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulizing Crohn's Disease [DIVERGENCE 2]: a Phase 2, Randomized, Placebo-Controlled Trial.
    J Crohns Colitis. 2024 Feb 16:jjae003. doi: 10.1093.
    >> Share

  36. PRENTICE R, Flanagan E, Wright E, Prideaux L, et al
    Thiopurine metabolite shunting in late pregnancy increases the risk of intrahepatic cholestasis of pregnancy in women with inflammatory bowel disease, and can be managed with split-dosing.
    J Crohns Colitis. 2024 Feb 15:jjae023. doi: 10.1093.
    >> Share

  37. VLADIMIROVA N, Terslev L, Attauabi M, Madsen G, et al
    Peripheral joint and enthesis involvement in patients with newly diagnosed inflammatory bowel disease: symptoms, clinical and ultrasound findings - a population-based cohort study.
    J Crohns Colitis. 2024 Feb 15:jjae022. doi: 10.1093.
    >> Share

  38. SIGVARDSSON I, Ludvigsson J, Andersson B, Stordal K, et al
    Tobacco smoke exposure in early childhood and later risk of inflammatory bowel disease: A Scandinavian birth cohort study.
    J Crohns Colitis. 2024 Feb 8:jjae020. doi: 10.1093.
    >> Share

  39. GHOSH S, Feagan BG, Ott E, Gasink C, et al
    Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
    J Crohns Colitis. 2024 Feb 4:jjae013. doi: 10.1093.
    >> Share

    January 2024
  40. KUO J, Uzunovic J, Jacobson A, Dourado M, et al
    Toxigenic Clostridium perfringens isolated from at-risk pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2024 Jan 24:jjae016. doi: 10.1093.
    >> Share

  41. DUAN M, Lu M, Diao Y, Cao L, et al
    Azathioprine plus exclusive enteral nutrition versus azathioprine monotherapy for the prevention of postoperative recurrence in patients with Crohn's disease: an open-label, single-centre, randomised controlled trial.
    J Crohns Colitis. 2024 Jan 22:jjae015. doi: 10.1093.
    >> Share

  42. YARUR AJ, Chiorean MV, Panes J, Jairath V, et al
    Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
    J Crohns Colitis. 2024 Jan 20:jjae007. doi: 10.1093.
    >> Share

  43. MAGRO F, Fernandes S, Patita M, Arroja B, et al
    The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients.
    J Crohns Colitis. 2024 Jan 19:jjae014. doi: 10.1093.
    >> Share


  44. Erratum to: Ustekinumab as Induction and Maintenance Therapy in Patients with Inflammatory Bowel Disease and Type II Autoimmune Pancreatitis: Report of Two Cases.
    J Crohns Colitis. 2024 Jan 19:jjae005. doi: 10.1093.
    >> Share

  45. BITTERLIN T, Valibouze C, Lenne X, Bruandet A, et al
    Hospital surgical volume-outcome relationship of postoperative morbidity for ileocolic resection in Crohn's disease: A French nationwide study of 4,205 patients.
    J Crohns Colitis. 2024 Jan 18:jjae010. doi: 10.1093.
    >> Share

  46. CHULKINA M, Rohmer C, McAninch S, Panganiban RP, et al
    Increased activity of MAPKAPK2 within mesenchymal cells as a target for inflammation associated fibrosis in Crohn's Disease.
    J Crohns Colitis. 2024 Jan 15:jjae009. doi: 10.1093.
    >> Share

  47. DESAI A, Hashash JG, Kochhar GS, Hayney MS, et al
    Recombinant Zoster Vaccine (RZV) is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study.
    J Crohns Colitis. 2024 Jan 15:jjae008. doi: 10.1093.
    >> Share

  48. RODRIGUEZ-ALCOLADO L, Grueso-Navarro E, Arias A, Lucendo AJ, et al
    Impact of HLA-DQA1 *05 Genotype in Immunogenicity and Failure to Treatment with Tumor Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2024 Jan 14:jjae006. doi: 10.1093.
    >> Share

  49. WONG C, van Oostrom J, Pittet V, Bossuyt P, et al
    Baseline Data and Measurement Instruments Reported In Observational Studies In Inflammatory Bowel Disease: Results From A Systematic Review.
    J Crohns Colitis. 2024 Jan 12:jjae004. doi: 10.1093.
    >> Share

  50. TIMAR AE, Parniczky A, Budai KA, Hernadfoi MV, et al
    Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations.
    J Crohns Colitis. 2024 Jan 8:jjae002. doi: 10.1093.
    >> Share

  51. PRUIJT MJ, de Voogd FAE, Montazeri NSM, van Etten-Jamaludin FS, et al
    DIAGNOSTIC ACCURACY OF INTESTINAL ULTRASOUND IN THE DETECTION OF INTRA-ABDOMINAL COMPLICATIONS IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    J Crohns Colitis. 2024 Jan 4:jjad215. doi: 10.1093.
    >> Share

    December 2023
  52. TAL N, Tzivinikos C, Gasparetto M, Serban DE, et al
    Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2023;17:1939-1948.
    >> Share

  53. HASSAN-ZAHRAEE M, Ye Z, Xi L, Dushin E, et al
    Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis.
    J Crohns Colitis. 2023 Dec 23:jjad213. doi: 10.1093.
    >> Share

  54. DOLINGER MT, Aronskyy I, Kellar A, Spencer E, et al
    Early Intestinal Ultrasound Response to Biologic Therapy Predicts Endoscopic Remission in Children with Ileal Crohn's Disease: Results from the Prospective Super Sonic Study.
    J Crohns Colitis. 2023 Dec 23:jjad216. doi: 10.1093.
    >> Share


  55. Correction to: Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Disease: A National Cohort Study from Sweden.
    J Crohns Colitis. 2023 Dec 23:jjad210. doi: 10.1093.
    >> Share

  56. VUYYURU SK, Solitano V, Singh S, Hanzel J, et al
    Scoring indices for perianal fistulizing Crohn's disease: A systematic review.
    J Crohns Colitis. 2023 Dec 21:jjad214. doi: 10.1093.
    >> Share

  57. HAMMOUDI N, Sachar D, D'Haens G, Reinisch W, et al
    Outcomes and endpoints of postoperative recurrence in Crohn's Disease: systematic review and consensus conference.
    J Crohns Colitis. 2023 Dec 19:jjad205. doi: 10.1093.
    >> Share

  58. NIEVA C, Pryor J, Williams GM, Hoedt EC, et al
    The Impact of Dietary Interventions on the Microbiota in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2023 Dec 15:jjad204. doi: 10.1093.
    >> Share

  59. VERMEIRE S, Danese S, Sandborn WJ, Schreiber S, et al
    Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2023 Dec 14:jjad199. doi: 10.1093.
    >> Share

  60. LEWIS A, Humphreys DT, Pan-Castillo B, Berti G, et al
    Epigenetic and metabolic reprogramming of fibroblasts in Crohn's disease strictures reveals histone deacetylases as therapeutic targets.
    J Crohns Colitis. 2023 Dec 9:jjad209. doi: 10.1093.
    >> Share

  61. COLOMBEL JF, Schreiber S, D'Haens G, Rizzo J, et al
    Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
    J Crohns Colitis. 2023 Dec 9:jjad206. doi: 10.1093.
    >> Share

  62. GROS B, Goodall M, Plevris N, Constantine-Cooke N, et al
    Real-World Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis.
    J Crohns Colitis. 2023 Dec 8:jjad187. doi: 10.1093.
    >> Share

  63. KAPIZIONI C, Desoki R, Lam D, Balendran K, et al
    Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource.
    J Crohns Colitis. 2023 Dec 2:jjad203. doi: 10.1093.
    >> Share

  64. VAN DER DOES DE WILLEBOIS EML, Sari C, Mookhoek A, Joustra V, et al
    The clinical relevance of an inflamed appendix in Crohn's disease.
    J Crohns Colitis. 2023 Dec 1:jjad202. doi: 10.1093.
    >> Share

  65. HU L, Wu S, Shu Y, Su K, et al
    Impact of Maternal Smoking, Offspring Smoking, and Genetic Susceptibility on Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2023 Dec 1:jjad200. doi: 10.1093.
    >> Share

    November 2023
  66. WATANABE K, Peyrin-Biroulet L, Danese S, Fujitani Y, et al
    Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study.
    J Crohns Colitis. 2023 Nov 29:jjad201. doi: 10.1093.
    >> Share

  67. KLOMBERG RCW, van der Wal HC, Aardoom MA, Kemos P, et al
    Improved clinical outcomes with early anti-tumour necrosis factor alpha therapy in children with newly diagnosed Crohn's disease: real world data from the international prospective PIBD-SETQuality inception cohort study.
    J Crohns Colitis. 2023 Nov 27:jjad197. doi: 10.1093.
    >> Share

  68. SCHELLENBERG C, Lagrange J, Ahmed MU, Arnone D, et al
    The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease.
    J Crohns Colitis. 2023 Nov 27:jjad198. doi: 10.1093.
    >> Share

  69. WANG Y, He Q, Yao D, Huang Y, et al
    Histologic image-based ensemble model to identify myenteric plexitis and predict endoscopic postoperative recurrence in Crohn's disease: a multicentre, retrospective study.
    J Crohns Colitis. 2023 Nov 24:jjad196. doi: 10.1093.
    >> Share

  70. BISHU S
    Nurturing the Gut, Moms with IBD and Their Babies.
    J Crohns Colitis. 2023;17:1705-1706.
    >> Share

  71. DORK R, Pelczar P, Shiri AM, Volmari A, et al
    Myeloid Cell-Specific Deletion of PDGFR-alpha Promotes Dysbiotic Intestinal Microbiota and thus Increased Colitis Susceptibility.
    J Crohns Colitis. 2023;17:1858-1869.
    >> Share

  72. PUGLIESE N, Dal Buono A, Armuzzi A
    Unveiling the Complexity of Porto-Sinusoidal Vascular Disorder in Inflammatory Bowel Disease: A Call for Further Investigation.
    J Crohns Colitis. 2023;17:1892.
    >> Share

  73. REVES J, Mascarenhas A, Jose Temido M, Morao B, et al
    Early intervention with biologic therapy in Crohn s disease: how early is early?
    J Crohns Colitis. 2023;17:1752-1760.
    >> Share

  74. SCHULZE LL, Becker E, Dedden M, Liu LJ, et al
    Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
    J Crohns Colitis. 2023;17:1817-1832.
    >> Share

  75. MEHTA S
    Intestinal Failure: A Small but Imperfectly Phenotyped Complication of Crohn's Disease.
    J Crohns Colitis. 2023 Nov 21:jjad154. doi: 10.1093.
    >> Share

  76. ROCHA CH, Walshe M, Birch S, Sabic K, et al
    Clinical predictors of early and late endoscopic recurrence following ileocolonic resection in Crohn's disease.
    J Crohns Colitis. 2023 Nov 17:jjad186. doi: 10.1093.
    >> Share

  77. RONSIN C, Le Berre C, Ville S
    Kidney injuries as Extra Intestinal Manifestation of Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Nov 15:jjad191. doi: 10.1093.
    >> Share

  78. VERSTOCKT B, Vermeire S, Peyrin-Biroulet L, Mosig R, et al
    The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
    J Crohns Colitis. 2023 Nov 11:jjad192. doi: 10.1093.
    >> Share

  79. SZEKELY H, Th LMT, Rancz A, Walter A, et al
    Anti-tumor necrosis factor alpha versus corticosteroids: a threefold difference in the occurence of venous thromboembolism in Inflammatory Bowel Disease - a systematic review and meta-analysis.
    J Crohns Colitis. 2023 Nov 11:jjad193. doi: 10.1093.
    >> Share

  80. TANDON P, Huang VW, Feig DS, Saskin R, et al
    Differences in Healthcare Utilization in Women with and without Inflammatory Bowel Diseases During Preconception, Pregnancy and Postpartum: A Population-Based Cohort Study.
    J Crohns Colitis. 2023;17:1587-1595.
    >> Share

  81. DRUVEFORS E, Myrelid P, Andersson RE, Landerholm K, et al
    Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Diesase: A National Cohort Study from Sweden.
    J Crohns Colitis. 2023;17:1631-1638.
    >> Share

  82. RAINE T, Ishiguro Y, Rubin DT, Finney-Hayward T, et al
    Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: a Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
    J Crohns Colitis. 2023 Nov 6:jjad190. doi: 10.1093.
    >> Share

  83. LIU Z, Alexander JL, Eng KY, Ibraheim H, et al
    Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
    J Crohns Colitis. 2023 Nov 6:jjad182. doi: 10.1093.
    >> Share

  84. VERMEIRE S, Hanzel J, Lowenberg M, Ferrante M, et al
    Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
    J Crohns Colitis. 2023 Nov 2:jjad179. doi: 10.1093.
    >> Share

  85. ROBLIN X, Nancey S, Papamichael K, Duru G, et al
    Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease.
    J Crohns Colitis. 2023 Nov 2:jjad188. doi: 10.1093.
    >> Share

  86. VUYYURU SK, Solitano V, Narula N, Lee MJ, et al
    Pharmacological therapies for the management of fistulising Crohn's disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2023 Nov 2:jjad185. doi: 10.1093.
    >> Share

  87. GISBERT JP, Chaparro M
    De-escalation of biological treatment in inflammatory bowel disease: A comprehensive review.
    J Crohns Colitis. 2023 Nov 1:jjad181. doi: 10.1093.
    >> Share

  88. CASAS DEZA D, Polo Cuadro C, de Francisco R, Vela Gonzalez M, et al
    Initial management of intraabdominal abscesses and preventive strategies for abscess recurrence in penetrating Crohn's disease: a national multicenter study based on ENEIDA registry.
    J Crohns Colitis. 2023 Nov 1:jjad184. doi: 10.1093.
    >> Share

    October 2023
  89. BOYD T, Araka EB, Kochar B, Ananthakrishnan AN, et al
    Differences in Management and Outcomes of Older and Younger Adults with Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2023 Oct 28:jjad183. doi: 10.1093.
    >> Share

  90. COHEN NA, Weber CR, Cheng JX, Choi D, et al
    Ozanimod-Exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histologic Changes.
    J Crohns Colitis. 2023 Oct 25:jjad174. doi: 10.1093.
    >> Share

  91. ASSCHER VER, Rodriguez Girondo MDM, Fens J, Waars SN, et al
    Frailty screening associates with hospitalization and decline in quality of life and functional status in older patients with inflammatory bowel disease.
    J Crohns Colitis. 2023 Oct 23:jjad175. doi: 10.1093.
    >> Share

  92. MULLER M, Broseus J, Guilloteau A, Wasse S, et al
    Lymphoma In Patients With Inflammatory Bowel Disease: A Multicenter Collaborative Study Between Getaid And Lysa.
    J Crohns Colitis. 2023 Oct 18:jjad177. doi: 10.1093.
    >> Share

  93. ALIBERT L, Betton L, Falcoz A, Manceau G, et al
    Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
    J Crohns Colitis. 2023 Oct 18:jjad176. doi: 10.1093.
    >> Share

  94. ROBLIN X, Paul S
    Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis?
    J Crohns Colitis. 2023 Oct 17:jjad167. doi: 10.1093.
    >> Share

  95. RYMARCZYK D, Schultz W, Borowa A, Friedman JR, et al
    Deep learning models capture histological disease activity in Crohn's Disease and Ulcerative Colitis with high fidelity.
    J Crohns Colitis. 2023 Oct 10:jjad171. doi: 10.1093.
    >> Share

  96. VERSTOCKT B, Pivorunas V, Mahi NA, Smaoui N, et al
    Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
    J Crohns Colitis. 2023 Oct 6:jjad170. doi: 10.1093.
    >> Share

  97. FERRANTE M, Irving PM, Abreu MT, Axler J, et al
    Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
    J Crohns Colitis. 2023 Oct 5:jjad168. doi: 10.1093.
    >> Share

    September 2023
  98. ATREYA R, Kuhbacher T, Waldner MJ, Hirschmann S, et al
    Submucosal injection of the RNA oligonucleotide GUT-1 in active ulcerative colitis patients: A randomized, double-blind, placebo-controlled phase 2a induction trial.
    J Crohns Colitis. 2023 Sep 30:jjad162. doi: 10.1093.
    >> Share

  99. BAI BYH, Reppell M, Smaoui N, Waring JF, et al
    Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn's disease patients.
    J Crohns Colitis. 2023 Sep 30:jjad166. doi: 10.1093.
    >> Share

  100. BONAZ B, Sinniger V
    Targeting the Vagus Nerve to Treat Inflammatory Bowel Disease?
    J Crohns Colitis. 2023 Sep 21:jjad149. doi: 10.1093.
    >> Share

  101. D'HAENS G, Eberhardson M, Cabrijan Z, Danese S, et al
    Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn's disease patients: a prospective open label study.
    J Crohns Colitis. 2023 Sep 21:jjad151. doi: 10.1093.
    >> Share

  102. FOCHT G, Turner D
    Lemman Index in pediatric Crohn's disease - evidence is accumulating.
    J Crohns Colitis. 2023 Sep 14:jjad161. doi: 10.1093.
    >> Share

  103. JEW M, Meserve J, Eisenstein S, Jairath V, et al
    Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn's Disease in the Biologic Era: An Updated Systematic Review with Meta-Analysis.
    J Crohns Colitis. 2023 Sep 14:jjad159. doi: 10.1093.
    >> Share

  104. VIOLA A, Li Voti R, Bivacqua C, de Francesco C, et al
    Mitigating the risk of Tofacitinib-induced adverse events in the elderly population with Ulcerative Colitis.
    J Crohns Colitis. 2023 Sep 13:jjad158. doi: 10.1093.
    >> Share

  105. BEHESHTI MAAL A, Shahrbaf MA, Sadri B, Hossein-Khannazer N, et al
    Prevalence of hepatobiliary manifestations in inflammatory bowel disease: a GRADE assessed systematic review and meta-analysis on more than 1.7 million patients.
    J Crohns Colitis. 2023 Sep 11:jjad157. doi: 10.1093.
    >> Share

  106. HARNIK S, Abitbol CM, Haj Natour O, Yavzori M, et al
    Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study.
    J Crohns Colitis. 2023 Sep 11:jjad156. doi: 10.1093.
    >> Share

  107. NIELSEN KR, Midjord J, Lophaven SN, Langholz E, et al
    The incidence and prevalence of inflammatory bowel disease continues to increase in the Faroe Islands - a cohort study from 1960-2020.
    J Crohns Colitis. 2023 Sep 5:jjad155. doi: 10.1093.
    >> Share

  108. SINGH A, Midha V, Kaur K, Mahajan R, et al
    Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective, open-label, randomized, pilot study.
    J Crohns Colitis. 2023 Sep 1:jjad153. doi: 10.1093.
    >> Share

    August 2023
  109. DANESE S, Panaccione R, Abreu MT, Rubin DT, et al
    Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension.
    J Crohns Colitis. 2023 Aug 31:jjad146. doi: 10.1093.
    >> Share

  110. TRINH S, Andrew B, Vasudevan A
    6-mercaptopurine in ulcerative colitis: the potential of upfront dosing with allopurinol.
    J Crohns Colitis. 2023 Aug 29:jjad150. doi: 10.1093.
    >> Share

  111. PIAZZA O SED N, Noviello D, Filippi E, Conforti F, et al
    Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicenter prospective cohort study.
    J Crohns Colitis. 2023 Aug 26:jjad152. doi: 10.1093.
    >> Share

  112. MILO F, Imondi C, D'Amore C, Angelino G, et al
    Short Term Psychodynamic Psychotherapy in addition to standard medical therapy increases clinical remission in Adolescents and Young Adults with Inflammatory Bowel Disease: a randomised controlled trial.
    J Crohns Colitis. 2023 Aug 24:jjad145. doi: 10.1093.
    >> Share

  113. REINISCH W, Pradhan V, Ahmad S, Zhang Z, et al
    Alternative endoscopy reading paradigms determine score reliability and effect size in ulcerative colitis.
    J Crohns Colitis. 2023 Aug 24:jjad134. doi: 10.1093.
    >> Share

  114. FEAKINS R, Borralho Nunes P, Driessen A, Gordon IO, et al
    Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper.
    J Crohns Colitis. 2023 Aug 22:jjad142. doi: 10.1093.
    >> Share

  115. WEWER MD, Jansson S, Malham M, Burisch J, et al
    Disease Activity Patterns of Paediatric Inflammatory Bowel Disease - A Danish Nationwide Cohort Study (1996-2018).
    J Crohns Colitis. 2023 Aug 21:jjad144. doi: 10.1093.
    >> Share

  116. QIAN W, Xu Y, Wen W, Huang L, et al
    Exosomal miR-103a-3p from Crohn's Creeping Fat-Derived Adipose-Derived Stem Cells Contributes to Intestinal Fibrosis by Targeting TGFBR3 and Activating Fibroblasts.
    J Crohns Colitis. 2023;17:1291-1308.
    >> Share

  117. HU X, Jiao F, Deng J, Zhou Z, et al
    Intestinal Epithelial Cell-specific Deletion of Cytokine-inducible SH2-containing Protein Alleviates Experimental Colitis in Ageing Mice.
    J Crohns Colitis. 2023;17:1278-1290.
    >> Share

  118. GORDON H, Rodger B, Lindsay JO, Stagg AJ, et al
    Recruitment and Residence of Intestinal T Cells - Lessons for Therapy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2023;17:1326-1341.
    >> Share

  119. WRIGHT EK, Chaparro M, Gionchetti P, Hamilton AL, et al
    Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically.
    J Crohns Colitis. 2023 Aug 18:jjad140. doi: 10.1093.
    >> Share

  120. KIM K, Park S, Lee Y, Baek J, et al
    Transcriptomic Profiling and Cellular Composition of Creeping Fat in Crohn's disease.
    J Crohns Colitis. 2023 Aug 18:jjad141. doi: 10.1093.
    >> Share


  121. Corrigendum to: Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
    J Crohns Colitis. 2023 Aug 17:jjad136. doi: 10.1093.
    >> Share

  122. PELTON M, Ssentongo P, Sun A, Groff D, et al
    Race & Ethnic Representation in Crohn's Disease Trials of Biologic and Small Molecule Medications: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023 Aug 16:jjad138. doi: 10.1093.
    >> Share

  123. SCHREIBER S, Danese S, Dignass A, Domenech E, et al
    Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations.
    J Crohns Colitis. 2023 Aug 16:jjad130. doi: 10.1093.
    >> Share

  124. RANJAN MK, Kumar P, Kumar Vuyyuru S, Kante B, et al
    Thiopurines have sustained long-term effectiveness in patients with inflammatory bowel disease which is independent of disease duration at initiation: A propensity score matched analysis.
    J Crohns Colitis. 2023 Aug 16:jjad135. doi: 10.1093.
    >> Share

  125. WIESE JJ, Manna S, Kuhl AA, Fasci A, et al
    Myenteric plexus immune cell infiltrations and neurotransmitter expression in Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2023 Aug 11:jjad122. doi: 10.1093.
    >> Share

  126. LIN S, Hannon E, Reppell M, Waring JF, et al
    Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease.
    J Crohns Colitis. 2023 Aug 8:jjad133. doi: 10.1093.
    >> Share

  127. VERMEIRE S, Feagan BG, Peyrin-Biroulet L, Oortwijn A, et al
    Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
    J Crohns Colitis. 2023 Aug 4:jjad123. doi: 10.1093.
    >> Share

  128. KRISHNAMOORTHY A, Chandrapalan S, Ahmed M, Arasaradnam RP, et al
    The Diagnostic Utility of Volatile Organic Compounds in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023 Aug 4:jjad132. doi: 10.1093.
    >> Share

  129. HURYCH J, Mascellani Bergo A, Lerchova T, Hlinakova L, et al
    Faecal bacteriome and metabolome profiles associated with decreased mucosal inflammatory activity upon anti-TNF therapy in paediatric Crohn's disease.
    J Crohns Colitis. 2023 Aug 1:jjad126. doi: 10.1093.
    >> Share

  130. BRODERSEN JB, Jensen MD, Leenhardt R, Kjeldsen J, et al
    Artificial intelligence-assisted analysis of pan-enteric capsule endoscopy in patients with suspected Crohn's disease. A study on diagnostic performance.
    J Crohns Colitis. 2023 Aug 1:jjad131. doi: 10.1093.
    >> Share

  131. JOUSTRA V, Li Yim AYF, van Gennep S, Hageman I, et al
    Peripheral blood DNA methylation signatures and response to tofacitinib in moderate-to-severe ulcerative colitis.
    J Crohns Colitis. 2023 Aug 1:jjad129. doi: 10.1093.
    >> Share

  132. GUADAGNOLI L, Horrigan J, Walentynowicz M, Salwen-Deremer JK, et al
    Sleep quality drives next day pain and fatigue in adults with inflammatory bowel disease: A short report.
    J Crohns Colitis. 2023 Aug 1:jjad128. doi: 10.1093.
    >> Share

    July 2023
  133. KIM K, Oh SJ, Lee J, Kwon A, et al
    Regulatory Variants on the Leukocyte Immunoglobulin-Like Receptor Gene Cluster are Associated with Crohn's Disease and Interact with Regulatory Variants for TAP2.
    J Crohns Colitis. 2023 Jul 31:jjad127. doi: 10.1093.
    >> Share

  134. CARON B, Jairath V, Laurent V, Stoker J, et al
    Defining magnetic resonance imaging treatment response and remission in Crohn's disease: a systematic review.
    J Crohns Colitis. 2023 Jul 31:jjad125. doi: 10.1093.
    >> Share

  135. GARCIA MJ, Rivero M, Fernandez-Clotet A, de Francisco R, et al
    Comparative Study Of The Effectiveness Of Vedolizumab Versus Ustekinumab After Anti-Tnf Failure In Crohn's Disease (Versus-Cd): Data From Eneida Registry.
    J Crohns Colitis. 2023 Jul 31:jjad124. doi: 10.1093.
    >> Share

  136. UNGARO RC, Kadali H, Zhang W, Adsul S, et al
    Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
    J Crohns Colitis. 2023 Jul 26:jjad113. doi: 10.1093.
    >> Share

  137. ATIA O, Friss C, Focht G, Magen Rimon R, et al
    Durability of the first biologic in patients with Crohn's disease: A nationwide study from the epi-IIRN.
    J Crohns Colitis. 2023 Jul 19:jjad121. doi: 10.1093.
    >> Share

  138. PARONI M, Leccese G, Ranzani V, Moschetti G, et al
    An intestinal Th17 subset is associated with inflammation in Crohn's Disease and activated by adherent-invasive Escherichia coli (AIEC).
    J Crohns Colitis. 2023 Jul 18:jjad119. doi: 10.1093.
    >> Share

  139. UEDA T, Koyama F, Sugita A, Ikeuchi H, et al
    Endoscopic lesions of postoperative anastomotic area in patients with Crohn's disease in the biologic era: A Japanese multi-center nationwide cohort study.
    J Crohns Colitis. 2023 Jul 14:jjad116. doi: 10.1093.
    >> Share

  140. HUININK STB, Thomassen D, Steyerberg EW, Pauwels RWM, et al
    Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 patients from 12 studies.
    J Crohns Colitis. 2023 Jul 12:jjad118. doi: 10.1093.
    >> Share

  141. SANDS BE, Schreiber S, Blumenstein I, Chiorean MV, et al
    Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.
    J Crohns Colitis. 2023 Jul 12:jjad112. doi: 10.1093.
    >> Share

  142. GONCZI L, Lakatos L, Golovics PA, Ilias A, et al
    Declining trends of reoperations and disease behavior progression in Crohn's disease over different therapeutic eras - a prospective population-based study from western Hungary between 1977-2020, data from the Veszprem cohort.
    J Crohns Colitis. 2023 Jul 9:jjad117. doi: 10.1093.
    >> Share

  143. GILMORE R, Tan L, Fernandes R, An YK, et al
    Upadacitinib Salvage Therapy for Infliximab experienced patients with Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2023 Jul 9:jjad115. doi: 10.1093.
    >> Share

  144. BRYANT RV, Travis SPL
    APOLLO Has Landed: PROMS and Histology in UC.
    J Crohns Colitis. 2023;17:1027-1028.
    >> Share

  145. UZZAN M, Bouhnik Y, Abreu M, Ahmad HA, et al
    Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
    J Crohns Colitis. 2023;17:1066-1078.
    >> Share

  146. LEDDER O, Turner D
    Multi-item Measures for Paediatric Inflammatory Bowel Diseases: The ABCs of All Those Acronyms.
    J Crohns Colitis. 2023;17:1154-1168.
    >> Share

  147. GRIMSDOTTIR S, Attauabi M, Kristine Dahl E, Burisch J, et al
    Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases.
    J Crohns Colitis. 2023;17:1139-1153.
    >> Share

  148. ALEXANDERSSON BT, Andreasson A, Hedin C, Broms G, et al
    Inflammatory bowel disease is not linked to a higher rate of adverse events in colonoscopy - a nationwide population-based study in Sweden.
    J Crohns Colitis. 2023 Jul 4:jjad114. doi: 10.1093.
    >> Share

  149. SCHREIBER S, Rubin DT, Ng SC, Peyrin-Biroulet L, et al
    Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
    J Crohns Colitis. 2023 Jul 4:jjad104. doi: 10.1093.
    >> Share

    June 2023
  150. PARIGI TL, Cannatelli R, Nardone OM, Zammarchi I, et al
    Neutrophil-only histological assessment of ulcerative colitis correlates with endoscopic activity and predicts long-term outcomes in a multicenter study.
    J Crohns Colitis. 2023 Jun 30:jjad110. doi: 10.1093.
    >> Share

  151. SEETHARAMAN J, Srivastava A, Yadav RR, Singh SK, et al
    Visceral fat indices: Do they help differentiate Crohn's disease and Intestinal tuberculosis in children?
    J Crohns Colitis. 2023 Jun 30:jjad109. doi: 10.1093.
    >> Share

  152. GORDON H, Burisch J, Ellul P, Karmiris K, et al
    ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Jun 23:jjad108. doi: 10.1093.
    >> Share

  153. FENG R, Tian Z, Mao R, Ma R, et al
    Gut microbiome generated phenylacetylglutamine from dietary protein is associated with Crohn's Disease and exacerbates colitis in mouse model possibly via platelet activation.
    J Crohns Colitis. 2023 Jun 23:jjad098. doi: 10.1093.
    >> Share

  154. MATHEWS SN, Lukin DJ
    Shifting the Inflammatory Balance in Ulcerative Colitis Through Diet: A Mediterranean Diet Pattern is Associated with Improvements in Dysbiosis and Disease Activity.
    J Crohns Colitis. 2023 Jun 23:jjad095. doi: 10.1093.
    >> Share

  155. YU N, Sriranganathan D, Walker GJ, Sazonovs A, et al
    Prevalence of NUDT15 genetic variants and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2023 Jun 22:jjad107. doi: 10.1093.
    >> Share

  156. BURISCH J, Safroneeva E, Laoun R, Ma C, et al
    Lack of benefit for early escalation to advanced therapies in ulcerative colitis: critical appraisal of current evidence.
    J Crohns Colitis. 2023 Jun 22:jjad106. doi: 10.1093.
    >> Share

  157. KOPCZYNSKA M, Crooks B, Deutsch L, Conley T, et al
    Disease recurrence and long-term outcomes following the development of intestinal failure in Crohn's disease: over 20 years of experience from a national reference centre.
    J Crohns Colitis. 2023 Jun 21:jjad105. doi: 10.1093.
    >> Share

  158. FOCHT G, Kuint RC, Greer MC, Pratt LT, et al
    Prospective Validation of the Lemann Index in Children: A Report From the Multicentre Image Kids Study.
    J Crohns Colitis. 2023;17:943-949.
    >> Share

  159. KANTASIRIPITAK W, Wicha SG, Thomas D, Hoffman I, et al
    A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2023;17:896-908.
    >> Share

  160. GISBERT JP, Chaparro M
    Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?
    J Crohns Colitis. 2023;17:995-1009.
    >> Share

  161. WEBER MC, Bauer J, Buck A, Clees Z, et al
    Perioperative Low-Dose Prednisolone Treatment Has Beneficial Effects on Postoperative Recovery and Anastomotic Healing in a Murine Colitis Model.
    J Crohns Colitis. 2023;17:950-959.
    >> Share

  162. SOLITANO V, Vuyyuru SK, MacDonald JK, Zayadi A, et al
    Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis.
    J Crohns Colitis. 2023 Jun 15:jjad100. doi: 10.1093.
    >> Share

  163. JANSEN FM, van Linschoten RCA, Kievit W, Smits LJT, et al
    Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn's disease patients in stable remission: the randomised controlled LADI trial.
    J Crohns Colitis. 2023 Jun 13:jjad101. doi: 10.1093.
    >> Share

  164. MATINI L, Chapman TP, Kantschuster R, Wilson J, et al
    Development of the Escalation of Therapy or Intervention (ETI) calculator for patients with ulcerative colitis using ePROMS.
    J Crohns Colitis. 2023 Jun 12:jjad099. doi: 10.1093.
    >> Share

  165. EDER P, Verstock B, Culver E, Dragoni G, et al
    Autoimmune pancreatitis in patients with inflammatory bowel disease - a real-world multicentre collaborative ECCO CONFER study.
    J Crohns Colitis. 2023 Jun 7:jjad097. doi: 10.1093.
    >> Share

  166. SUN Z, Braga-Neto MB, Xiong Y, Bhagwate AV, et al
    Hypomethylation and overexpression of Th17-associated genes is a hallmark of intestinal CD4+ lymphocytes in Crohn's disease.
    J Crohns Colitis. 2023 Jun 6:jjad093. doi: 10.1093.
    >> Share

  167. SABINO J, Tarassishin L, Eisele C, Hawkins K, et al
    Influence of Early Life Factors, including Breastmilk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Jun 6:jjad096. doi: 10.1093.
    >> Share

  168. HOLTEN KA, Bernklev T, Opheim R, Johansen I, et al
    Fatigue in patients with newly diagnosed inflammatory bowel disease: Results from a prospective inception cohort, the IBSEN III study.
    J Crohns Colitis. 2023 Jun 5:jjad094. doi: 10.1093.
    >> Share

    May 2023
  169. BRUGGELING CE, Te Groen M, Garza DR, van Heeckeren Tot Overlaer F, et al
    Bacterial oncotraits rather than spatial organization are associated with dysplasia in ulcerative colitis.
    J Crohns Colitis. 2023 May 27:jjad092. doi: 10.1093.
    >> Share

  170. MOTWANI KK, Hashash JG, Farraye FA, Kappelman MD, et al
    Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
    J Crohns Colitis. 2023 May 26:jjad085. doi: 10.1093.
    >> Share


  171. Correction to: Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    J Crohns Colitis. 2023 May 24:jjad082. doi: 10.1093.
    >> Share

  172. PEYRIN-BIROULET L, Arenson E, Rubin DT, Siegel CA, et al
    A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes Score, Robarts Histopathology Index, and Nancy Index.
    J Crohns Colitis. 2023 May 24:jjad087. doi: 10.1093.
    >> Share

  173. HONAP S, Buisson A, Danese S, Laurent B, et al
    Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 May 23:jjad090. doi: 10.1093.
    >> Share

  174. PIERRE N, Vieujean S, Peyrin-Biroulet L, Meuwis MA, et al
    Defining biological remission in Crohn's disease: interest, challenges and future directions.
    J Crohns Colitis. 2023 May 19:jjad086. doi: 10.1093.
    >> Share

  175. STAFFORD IS, Ashton JJ, Mossotto E, Cheng G, et al
    Supervised machine learning classifies inflammatory bowel disease patients by subtype using whole exome sequencing data.
    J Crohns Colitis. 2023 May 19:jjad084. doi: 10.1093.
    >> Share

  176. KABIR M, Thomas-Gibson S, Tozer PJ, Warusavitarne J, et al
    DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making.
    J Crohns Colitis. 2023 May 12:jjad083. doi: 10.1093.
    >> Share

  177. ITZKOWITZ S, Farraye FA, Limburg P, Gagrat Z, et al
    Assessment of Stool DNA Markers to Detect Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: A Multi-site Case-control Study.
    J Crohns Colitis. 2023 May 11:jjad069. doi: 10.1093.
    >> Share

  178. OHLMANN H, Lanters LR, Theysohn N, Langhorst J, et al
    Distinct alterations in central pain processing of visceral and somatic pain in quiescent ulcerative colitis compared to irritable bowel syndrome and health.
    J Crohns Colitis. 2023 May 10:jjad080. doi: 10.1093.
    >> Share

  179. IRVING PM
    Thiopurines for Ulcerative Colitis: Old Favourite or Old Hat?
    J Crohns Colitis. 2023 May 4:jjad062. doi: 10.1093.
    >> Share

  180. BAI L, Dermadi D, Kalesinskas L, Dvorak M, et al
    Mass-Cytometry-Based Quantification of Global Histone Post-Translational Modifications at Single-Cell Resolution Across Peripheral Immune Cells in IBD.
    J Crohns Colitis. 2023;17:804-815.
    >> Share

  181. GODNY L, Svolos V, Williams AJ, Czuber-Dochan W, et al
    Multidisciplinary Perinatal Care in IBD.
    J Crohns Colitis. 2023;17:663-680.
    >> Share

  182. VERMEIRE S, Solitano V, Peyrin-Biroulet L, Tilg H, et al
    Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.
    J Crohns Colitis. 2023 May 2:jjad067. doi: 10.1093.
    >> Share

    April 2023
  183. MCCURDY JD, Weng R, Parlow S, Dawkins YM, et al
    Video capsule endoscopy can identify occult luminal Crohn's disease in patients with isolated perianal fistulas.
    J Crohns Colitis. 2023 Apr 26:jjad078. doi: 10.1093.
    >> Share

  184. ATIA O, Friss C, Ledderman N, Greenfeld S, et al
    Thiopurines have longer treatment durability than methotrexate in adults and children with Crohn's Disease: a nationwide analysis from the epi-IIRN cohort.
    J Crohns Colitis. 2023 Apr 26:jjad076. doi: 10.1093.
    >> Share

  185. KURIAKOSE KUZHIYANJAL AJ, Nigam GB, Antoniou GA, Farraye FA, et al
    Management of Inflammatory Bowel Disease Using E-Health Technologies: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023 Apr 26:jjad075. doi: 10.1093.
    >> Share

  186. TSCHURTSCHENTHALER M, Verstockt B
    Targeting a Hallmark of Crohn's Disease: Browning of the Hypertrophic Mesenteric Adipose Tissue as a Novel Strategy to Reduce Inflammation?
    J Crohns Colitis. 2023 Apr 26:jjad059. doi: 10.1093.
    >> Share

  187. ALSOUD D, Ho J, Verstockt B
    The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease.
    J Crohns Colitis. 2023 Apr 26:jjad077. doi: 10.1093.
    >> Share

  188. HASKEY N, Estaki M, Ye J, Shim RK, et al
    A Mediterranean Diet Pattern improves intestinal inflammation concomitant with reshaping of the bacteriome in ulcerative colitis: A randomized controlled trial.
    J Crohns Colitis. 2023 Apr 24:jjad073. doi: 10.1093.
    >> Share

  189. LAURI G, D'Amico F, Allocca M, Palumbo D, et al
    Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases.
    J Crohns Colitis. 2023 Apr 22:jjad072. doi: 10.1093.
    >> Share

  190. ALLOCCA M, Dell'Avalle C, Furfaro F, Zilli A, et al
    Early intestinal ultrasound predicts long-term endoscopic response to biologics in ulcerative colitis.
    J Crohns Colitis. 2023 Apr 21:jjad071. doi: 10.1093.
    >> Share

  191. GORELIK Y, Ghersin I, Shlon D, Friss C, et al
    Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: a report from the epi-IIRN.
    J Crohns Colitis. 2023 Apr 21:jjad070. doi: 10.1093.
    >> Share

  192. LIGHTNER AL, Reese J, Ream J, Nachand D, et al
    A Phase IB/IIA Study of Allogeneic, Bone Marrow-derived, Mesenchymal Stem Cells for the Treatment of Refractory Ileal-anal Anastomosis and Peripouch Fistulas in the Setting of Crohn's Disease of the Pouch.
    J Crohns Colitis. 2023;17:480-488.
    >> Share

  193. CAO D, Qian K, Zhao Y, Hong J, et al
    Association of Neutrophil Extracellular Traps with Fistula Healing in Patients with Complex Perianal Fistulizing Crohn's Disease.
    J Crohns Colitis. 2023;17:580-592.
    >> Share

  194. VIEUJEAN S, De Vos M, Paridaens K, Daftary GS, et al
    Fertility and Assisted Reproductive Technologies Outcomes of Women with Non-surgically Managed Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2023;17:614-632.
    >> Share

  195. NIGHOT M, Liao PL, Morris N, McCarthy D, et al
    Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental Colitis.
    J Crohns Colitis. 2023;17:565-579.
    >> Share

  196. CHEN J, Wellens J, Kalla R, Fu T, et al
    Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank.
    J Crohns Colitis. 2023;17:535-552.
    >> Share

  197. CHUGH R, Braga-Neto MB, Fredrick TW, Ramos GP, et al
    Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
    J Crohns Colitis. 2023;17:504-512.
    >> Share

  198. SHARMA T, Ma C, Sedano R, Hanzel J, et al
    Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023;17:644-658.
    >> Share

  199. ELMAGHRAWY K, Fleming P, Fitzgerald K, Cooper S, et al
    The Oral Microbiome in Treatment-Naive Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy.
    J Crohns Colitis. 2023;17:553-564.
    >> Share

  200. ZHAO J, Lin Z, Ying P, Zhao Z, et al
    circSMAD4 Promotes Experimental Colitis and Impairs Intestinal Barrier Functions by Targeting Janus Kinase 2 Through Sponging miR-135a-5p.
    J Crohns Colitis. 2023;17:593-613.
    >> Share

  201. DRAGONI G, Allocca M, Myrelid P, Noor NM, et al
    Results of the Eighth Scientific Workshop of ECCO: Diagnosing postoperative recurrence of Crohn's disease after an ileocolonic resection with ileocolonic anastomosis.
    J Crohns Colitis. 2023 Apr 18:jjad055. doi: 10.1093.
    >> Share

  202. RIVIERE P, Bislenghi G, Hammoudi N, Verstockt B, et al
    Results of the Eighth Scientific Workshop of ECCO: Pathophysiology and risk factors of postoperative Crohn's disease recurrence after an ileocolic resection.
    J Crohns Colitis. 2023 Apr 18:jjad054. doi: 10.1093.
    >> Share

  203. FERRANTE M, Pouillon L, Manosa M, Savarino E, et al
    Results of the Eighth Scientific Workshop of ECCO: Prevention and treatment of postoperative recurrence in patients with Crohn's disease undergoing an ileocolonic resection with ileocolonic anastomosis.
    J Crohns Colitis. 2023 Apr 18:jjad053. doi: 10.1093.
    >> Share

  204. YAZAKI T, Kawashima K, Ishihara S
    Azathioprine-induced porto-sinusoidal vascular disease complicated with esophageal varices in Crohn's disease patient - Case report.
    J Crohns Colitis. 2023 Apr 17:jjad066. doi: 10.1093.
    >> Share


  205. Erratum to: Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment.
    J Crohns Colitis. 2023 Apr 15:jjad044. doi: 10.1093.
    >> Share

  206. MAGRO F, Pai RK, Kobayashi T, Jairath V, et al
    Resolving Histologic Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programs.
    J Crohns Colitis. 2023 Apr 14:jjad050. doi: 10.1093.
    >> Share

  207. JANSEN D, Falony G, Vieira-Silva S, Simsek C, et al
    Community Types Of The Human Gut Virome Are Associated With Endoscopic Outcome In Ulcerative Colitis.
    J Crohns Colitis. 2023 Apr 13:jjad061. doi: 10.1093.
    >> Share

  208. DRAGONI G, Gottin M, Innocenti T, Lynch EN, et al
    "Correlation of ultrasound scores with endoscopic activity in Crohn's disease: a prospective exploratory study".
    J Crohns Colitis. 2023 Apr 6:jjad068. doi: 10.1093.
    >> Share

  209. DOHERTY J, O Morain N, Stack R, Tosetto M, et al
    Reduced serological response to COVID-19 booster vaccine is associated with reduced B cell memory in patients with Inflammatory Bowel Disease; VARIATION (VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON).
    J Crohns Colitis. 2023 Apr 5:jjad065. doi: 10.1093.
    >> Share

  210. FURUKAWA S, Mizushima T, Nakaya R, Shibata M, et al
    Darvadstrocel for Complex Perianal Fistulas in Japanese Adults with Crohn's Disease: A Phase 3 Study.
    J Crohns Colitis. 2023;17:369-378.
    >> Share

  211. JOHANSEN MP, Wewer MD, Nordholm-Carstensen A, Burisch J, et al
    Perianal Crohn's Disease and the Development of Colorectal and Anal Cancer: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2023;17:361-368.
    >> Share

  212. JOUSTRA V, van Sabben J, van der Does de Willebois E, Duijvestein M, et al
    Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn's Disease.
    J Crohns Colitis. 2023;17:318-328.
    >> Share

  213. WONG ECL, Moayyedi P, Narula N
    Beyond the White Pill: Advocating for Racial Diversity in IBD Trials.
    J Crohns Colitis. 2023;17:459-461.
    >> Share

  214. ASHTON JJ, Seaby EG, Beattie RM, Ennis S, et al
    NOD2 in Crohn's Disease-Unfinished Business.
    J Crohns Colitis. 2023;17:450-458.
    >> Share

    March 2023
  215. AXELRAD J, Olen O, Soderling J, Roelstraete B, et al
    Inflammatory Bowel Disease and Risk of Colorectal Polyps: A nationwide population-based cohort study from Sweden.
    J Crohns Colitis. 2023 Mar 30:jjad056. doi: 10.1093.
    >> Share

  216. CHEN LA, Oliva-Hemker M, Radin A, Weidner M, et al
    Longitudinal bile acid composition changes following fecal microbiota transplantation for Clostridioides difficile infection in children with and without underlying inflammatory bowel disease.
    J Crohns Colitis. 2023 Mar 29:jjad057. doi: 10.1093.
    >> Share

  217. JANKER L, Schuster D, Bortel P, Hagn G, et al
    Multi-omics empowered deep phenotyping of ulcerative colitis identifies biomarker signatures reporting functional remission states.
    J Crohns Colitis. 2023 Mar 24:jjad052. doi: 10.1093.
    >> Share

  218. FADEL MG, Geropoulos G, Warren OJ, Mills SC, et al
    Risks factors associated with the development of Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2023 Mar 24:jjad051. doi: 10.1093.
    >> Share

  219. DE CODES LMG, de Jesus ACC, de Codes JJG, Ferreira RF, et al
    Anorectal function and clinical characteristics associated with fecal incontinence in patients with Crohn's disease.
    J Crohns Colitis. 2023 Mar 23:jjad048. doi: 10.1093.
    >> Share

  220. ALLEZ M, Sands BE, Feagan BG, D'Haens G, et al
    A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn's Disease.
    J Crohns Colitis. 2023 Mar 20:jjad047. doi: 10.1093.
    >> Share

  221. RUNDE J, Veseli I, Fogarty EC, Watson AR, et al
    Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease.
    J Crohns Colitis. 2023 Mar 19:jjad031. doi: 10.1093.
    >> Share

  222. JONGSMA MME, Costes LMM, Tindemans I, Cozijnsen MA, et al
    Serum immune profiling in pediatric Crohn's disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments.
    J Crohns Colitis. 2023 Mar 19:jjad049. doi: 10.1093.
    >> Share

  223. ZUO L, Geng Z, Song X, Li J, et al
    Browning of mesenteric white adipose tissue in Crohn's disease: a new pathological change and therapeutic target.
    J Crohns Colitis. 2023 Mar 18:jjad046. doi: 10.1093.
    >> Share

  224. ROSS ADB, Zilbauer M
    Validation of IBD-associated Whole-blood DNA Methylation Changes-Where Do We Go From Here?
    J Crohns Colitis. 2023;17:151-152.
    >> Share

  225. HARVEY PR, Trudgill NJ
    Venous Thromboembolism Following Discharge from Hospital in Patients Admitted for Inflammatory Bowel Diseases-Authors' Reply.
    J Crohns Colitis. 2023;17:306.
    >> Share

  226. RIVIERE P, Pekow J, Hammoudi N, Wils P, et al
    Comparison of the Risk of Crohn's Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis.
    J Crohns Colitis. 2023;17:269-276.
    >> Share

  227. ARKENBOSCH JHC, Beelen EMJ, Dijkstra G, Romberg-Camps M, et al
    Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: a Prospective Study Based on Clinical Risk Stratification.
    J Crohns Colitis. 2023;17:221-230.
    >> Share

  228. GONCZI L, Lakatos L, Kurti Z, Golovics PA, et al
    Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn's Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018.
    J Crohns Colitis. 2023;17:240-248.
    >> Share

  229. SEBASTIAN S, Segal JP, Hedin C, Pellino G, et al
    ECCO Topical Review: Roadmap to Optimal Peri-Operative Care in IBD.
    J Crohns Colitis. 2023;17:153-169.
    >> Share

  230. DAI C, Huang YH
    Venous Thromboembolism Following Discharge from Hospital Among Patients Admitted for Inflammatory Bowel Diseases.
    J Crohns Colitis. 2023;17:305.
    >> Share

  231. LIANG ZX, Liu HS, Xiong L, Zeng ZW, et al
    GAS6 From CD200+ Adipose-Derived Stem Cells Mitigates Colonic Inflammation in a Macrophage-Dependent Manner.
    J Crohns Colitis. 2023;17:289-301.
    >> Share

  232. ALBUQUERQUE A, Cappello C, Stirrup O, Selinger CP, et al
    Anal high-risk human papillomavirus infection, squamous intraepithelial lesions and anal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2023 Mar 17:jjad045. doi: 10.1093.
    >> Share

  233. DOTAN I, Feagan BG, Taliadouros V, Oortwijn A, et al
    Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
    J Crohns Colitis. 2023 Mar 16:jjad039. doi: 10.1093.
    >> Share

  234. JIMBO K, Hosoi K, Suzuki M, Kyodo R, et al
    Accuracy of Transperineal Ultrasonography for Assessing Rectal Lesions in Pediatric Ulcerative Colitis: A Prospective Study.
    J Crohns Colitis. 2023 Mar 15:jjad035. doi: 10.1093.
    >> Share

  235. MACALUSO FS, Ventimiglia M, Orlando A
    Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies.
    J Crohns Colitis. 2023 Mar 13:jjad043. doi: 10.1093.
    >> Share

  236. JANSSEN LM, Creemers RH, van Bodegraven AA, Pierik MJ, et al
    A systematic review on long-term efficacy outcome measures in Crohn's disease patients.
    J Crohns Colitis. 2023 Mar 13:jjad037. doi: 10.1093.
    >> Share


  237. Erratum to: Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Mar 9:jjad028. doi: 10.1093.
    >> Share

  238. YAMAMOTO T, Nakase H, Watanabe K, Shinzaki S, et al
    Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn's Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn's Disease (iCREST-CD).
    J Crohns Colitis. 2023 Mar 4:jjad038. doi: 10.1093.
    >> Share

  239. STEENHOLDT C, Ovesen PD, Brynskov J, Seidelin JB, et al
    Tofacitinib for acute severe ulcerative colitis: a systematic review.
    J Crohns Colitis. 2023 Mar 1:jjad036. doi: 10.1093.
    >> Share

    February 2023
  240. LOWENBERG M, Volkers A, van Gennep S, Mookhoek A, et al
    Mercaptopurine for the treatment of ulcerative colitis - a randomised placebo-controlled trial.
    J Crohns Colitis. 2023 Feb 27:jjad022. doi: 10.1093.
    >> Share

  241. LAHARIE D, Mary JY
    Should we target complete endoscopic healing in patients with acute severe ulcerative colitis?
    J Crohns Colitis. 2023 Feb 25:jjad032. doi: 10.1093.
    >> Share

  242. QUEIROZ NSF, Cheifetz AS, Papamichael K
    Going Beyond a Treat-To-Target to a Treat-To-Clear and a Treat-To-Trough Therapeutic Strategy in Patients with Inflammatory Bowel Disease?
    J Crohns Colitis. 2023 Feb 24:jjad014. doi: 10.1093.
    >> Share

  243. WONG ECL, Dulai PS, Hasan B, Marshall JK, et al
    Combined Histologic and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared to Endoscopic Improvement Alone in Ulcerative Colitis: A Post-hoc Analysis of the VARSITY study.
    J Crohns Colitis. 2023 Feb 23:jjad033. doi: 10.1093.
    >> Share

  244. WINOGRODZKI T, Metwaly A, Grodziecki A, Liang W, et al
    TNF DeltaARE pigs: a translational Crohn;s Disease model.
    J Crohns Colitis. 2023 Feb 23:jjad034. doi: 10.1093.
    >> Share

  245. RIBALDONE DG, Vieujean S, Julsgaard M, Armandi A, et al
    Non-hepatic solid organ transplant in patients with inflammatory bowel disease: an ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2023 Feb 23:jjad030. doi: 10.1093.
    >> Share

  246. AHMAD HA, East JE, Panaccione R, Travis S, et al
    Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials.
    J Crohns Colitis. 2023 Feb 22:jjad029. doi: 10.1093.
    >> Share

  247. MENG G, Monaghan TM, Duggal NA, Tighe P, et al
    Microbial-Immune Crosstalk in Elderly-Onset Inflammatory Bowel Disease: Unchartered Territory.
    J Crohns Colitis. 2023 Feb 20:jjad025. doi: 10.1093.
    >> Share

  248. WANG Z, Gong J
    Causal effect of visceral adipose tissue accumulation on the inflammatory bowel disease: a Mendelian randomization study.
    J Crohns Colitis. 2023 Feb 20:jjad026. doi: 10.1093.
    >> Share

  249. RISPO A, Calabrese G, Testa A, Imperatore N, et al
    Hocus Pocus: The Role Of Handheld Ultrasonography In Predicting Disease Extension And Endoscopic Activity In Ulcerative Colitis.
    J Crohns Colitis. 2023 Feb 16:jjad024. doi: 10.1093.
    >> Share

  250. REZAZADEH ARDABILI A, van Esser D, Wintjens D, Cilissen M, et al
    Development and validation of a remote monitoring tool for assessment of mild, moderate, and severe infections in Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Feb 16:jjad023. doi: 10.1093.
    >> Share

  251. DONNELLY M, Ryan OK, Ryan EJ, Bass GA, et al
    Comparison of restorative proctocolectomy with and without defunctioning loop ileostomy in patients with ulcerative colitis - A systematic review and meta-analysis.
    J Crohns Colitis. 2023 Feb 13:jjad021. doi: 10.1093.
    >> Share


  252. Corrigendum to: Long-term Oncological Outcome of Segmental Versus Extended Colectomy for Colorectal Cancer in Crohn's Disease: Results from an International Multicentre Study.
    J Crohns Colitis. 2023 Feb 9:jjac158. doi: 10.1093.
    >> Share

  253. SCHREIBER S, Feagan BG, Peyrin-Biroulet L, Vermeire S, et al
    Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from SELECTION.
    J Crohns Colitis. 2023 Feb 9:jjad018. doi: 10.1093.
    >> Share

  254. REENAERS C, Gillard RP, Coimbra C, Gillard RM, et al
    Clinical and MRI evolution after local injection of bone marrow-derived mesenchymal stem cells in perianal fistulae in Crohn's disease: results from a prospective monocentric study.
    J Crohns Colitis. 2023 Feb 3:jjac192. doi: 10.1093.
    >> Share

    January 2023
  255. VERSTOCKT B, Pouillon L, Ballaux F, Jorissen C, et al
    Patient reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study.
    J Crohns Colitis. 2023 Jan 27:jjad015. doi: 10.1093.
    >> Share

  256. VERBURGT CM, Dunn KA, Ghiboub M, Lewis JD, et al
    Successful Dietary Therapy in Paediatric Crohn's Disease is Associated with Shifts in Bacterial Dysbiosis and Inflammatory Metabotype Towards Healthy Controls.
    J Crohns Colitis. 2023;17:61-72.
    >> Share

  257. SHARIP MT, Subramanian S
    IBD Risk-It Is All in the Family!
    J Crohns Colitis. 2023;17:28-29.
    >> Share

  258. TORRES J, Chaparro M, Julsgaard M, Katsanos K, et al
    European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation.
    J Crohns Colitis. 2023;17:1-27.
    >> Share

  259. CASAS-DEZA D, Lamuela-Calvo LJ, Gomollon F, Arbones-Mainar JM, et al
    Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
    J Crohns Colitis. 2023;17:83-91.
    >> Share

  260. AMIOT A, Rahier JF, Baert F, Nahon S, et al
    The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.
    J Crohns Colitis. 2023;17:37-48.
    >> Share

  261. SIMSEK M, Schepers F, Kaplan S, van Asseldonk D, et al
    Thioguanine is effective as maintenance therapy for inflammatory bowel disease: a prospective multicentre registry study.
    J Crohns Colitis. 2023 Jan 25:jjad013. doi: 10.1093.
    >> Share

  262. SHUBHAKAR A, Jansen BC, Adams AT, Reiding KR, et al
    Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Jan 24:jjad012. doi: 10.1093.
    >> Share

  263. CHANG MJ, Hao JW, Qiao J, Chen MR, et al
    A compendium of mucosal molecular characteristics provides novel perspectives on the treatment of ulcerative colitis.
    J Crohns Colitis. 2023 Jan 22:jjad011. doi: 10.1093.
    >> Share

  264. CAO S, Colonna M, Deepak P
    Pathogenesis of Perianal Fistulizing Crohn's Disease: Current knowledge, gaps in understanding and future research directions.
    J Crohns Colitis. 2023 Jan 19:jjad008. doi: 10.1093.
    >> Share

  265. SOSNOVSKI KE, Braun T, Amir A, Moshel D, et al
    GATA6-AS1 regulates intestinal epithelial mitochondrial functions, and its reduced expression is linked to intestinal inflammation and less favorable disease course in ulcerative colitis (UC).
    J Crohns Colitis. 2023 Jan 19:jjad006. doi: 10.1093.
    >> Share

  266. SUN Z, Liu MS
    Genetic evidence for causal relationship between body mass index and inflammatory bowel disease: a Mendelian randomisation study.
    J Crohns Colitis. 2023 Jan 19:jjad007. doi: 10.1093.
    >> Share

  267. GISBERT JP, Garcia MJ, Chaparro M
    Rescue therapies for steroid-refractory acute severe ulcerative colitis: A review.
    J Crohns Colitis. 2023 Jan 18:jjad004. doi: 10.1093.
    >> Share

  268. NOOR NM, Sousa P, Bettenworth D, Gomollon F, et al
    ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease.
    J Crohns Colitis. 2023 Jan 10:jjad001. doi: 10.1093.
    >> Share


  269. Corrigendum to: Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Jan 4:jjac195. doi: 10.1093.
    >> Share

    December 2022

  270. Erratum to: Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
    J Crohns Colitis. 2022 Dec 29:jjac180. doi: 10.1093.
    >> Share

  271. CHEN J, Zhou Y, Sun Y, Yuan S, et al
    Bi-directional Mendelian randomization analysis provides evidence for the causal involvement of dysregulation of CXCL9, CCL11 and CASP8 in the pathogenesis of ulcerative colitis.
    J Crohns Colitis. 2022 Dec 28:jjac191. doi: 10.1093.
    >> Share

  272. JE Y, Han K, Chun J, Kim Y, et al
    Association of Waist Circumference with the Risk of Inflammatory Bowel Disease: a Nationwide Cohort Study of 10 Million Individuals in Korea.
    J Crohns Colitis. 2022 Dec 23:jjac193. doi: 10.1093.
    >> Share

  273. WETWITTAYAKHLANG P, Gonczi L, Lakatos L, Kurti Z, et al
    Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras - Results from Western Hungarian Population-based Inception Cohort between 1977-2020.
    J Crohns Colitis. 2022 Dec 20:jjac188. doi: 10.1093.
    >> Share

  274. GORDON H, Biancone L, Fiorino G, Katsanos KH, et al
    ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.
    J Crohns Colitis. 2022 Dec 18:jjac187. doi: 10.1093.
    >> Share

  275. TAKAHASHI K, Shigeyasu K, Kondo Y, Gotoh K, et al
    RNA editing is a valuable biomarker for predicting carcinogenesis in ulcerative colitis.
    J Crohns Colitis. 2022 Dec 18:jjac186. doi: 10.1093.
    >> Share

  276. TAKENAKA K, Kawamoto A, Kitazume Y, Fujii T, et al
    Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn's disease.
    J Crohns Colitis. 2022 Dec 17:jjac185. doi: 10.1093.
    >> Share

  277. KHALILI H, Hakansson N, Casey K, Lopes E, et al
    Diet Quality and Risk of Older-Onset Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2022 Dec 15:jjac184. doi: 10.1093.
    >> Share

  278. CROUWEL F, Simsek M, de Boer MA, Mulder CJJ, et al
    Exposure to thioguanine during 117 pregnancies in women with inflammatory bowel disease.
    J Crohns Colitis. 2022 Dec 15:jjac183. doi: 10.1093.
    >> Share

  279. UCHIYAMA K, Takagi T, Mizushima K, Hirai Y, et al
    Mucosal addressin cell adhesion molecule 1 expression reflects mucosal inflammation and subsequent relapse in patients with ulcerative colitis.
    J Crohns Colitis. 2022 Dec 13:jjac182. doi: 10.1093.
    >> Share

  280. HAMON A, Cazals-Hatem D, Stefanescu C, Uzzan M, et al
    Crohn-like disease affecting small bowel due to monogenic SLCO2A1 mutations: First cases of Chronic Enteropathy Associated with SLCO2A1 gene (CEAS) in France.
    J Crohns Colitis. 2022 Dec 8:jjac181. doi: 10.1093.
    >> Share

  281. YANAI H, Kagramanova A, Knyazev O, Sabino J, et al
    Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
    J Crohns Colitis. 2022;16:1882-1892.
    >> Share

  282. LIU Z, Julsgaard M, Zhu X, Martin J, et al
    Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
    J Crohns Colitis. 2022;16:1835-1844.
    >> Share

  283. BHAT S, Rieder F
    Hypoxia-Inducible Factor 1-Alpha Stabilizers in the Treatment of Inflammatory Bowel Diseases: Oxygen as a Novel IBD Therapy?
    J Crohns Colitis. 2022;16:1924-1932.
    >> Share

  284. MITROVA K, Pipek B, Bortlik M, Bouchner L, et al
    Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
    J Crohns Colitis. 2022;16:1808-1815.
    >> Share

  285. HAMILTON AL, De Cruz P, Wright EK, Dervieux T, et al
    Non-invasive Serological Monitoring for Crohn's Disease Postoperative Recurrence.
    J Crohns Colitis. 2022;16:1797-1807.
    >> Share

  286. LEE C, Song JH, Cha YE, Chang DK, et al
    Intestinal Epithelial Responses to IL-17 in Adult Stem Cell-derived Human Intestinal Organoids.
    J Crohns Colitis. 2022;16:1911-1923.
    >> Share

  287. PELLINO G, Rottoli M, Mineccia M, Frontali A, et al
    Segmental Versus Total Colectomy for Crohn's Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study.
    J Crohns Colitis. 2022;16:1853-1861.
    >> Share

  288. ARP L, Jansson S, Wewer V, Burisch J, et al
    Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases - A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2022;16:1933-1945.
    >> Share

  289. BARBERIO B, Savarino E, Verstockt B, Fumery M, et al
    Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2022;16:1845-1852.
    >> Share

  290. BATTAT R
    Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived?
    J Crohns Colitis. 2022;16:1795-1796.
    >> Share

  291. MAHAJNA H, Verstockt B, Bergemalm D, Castiglione F, et al
    Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series.
    J Crohns Colitis. 2022 Dec 2:jjac179. doi: 10.1093.
    >> Share

    November 2022
  292. EL-ZIMAITY H, Shaffer SR, Riddell RH, Pai RK, et al
    Beyond Neutrophils for predicting relapse and remission in ulcerative colitis.
    J Crohns Colitis. 2022 Nov 25:jjac178. doi: 10.1093.
    >> Share

  293. KONTOLA K, Oksanen P, Huhtala H, Jussila A, et al
    Increasing incidence of inflammatory bowel disease with greatest change among the elderly: a nationwide study in Finland, 2000-2020.
    J Crohns Colitis. 2022 Nov 24:jjac177. doi: 10.1093.
    >> Share

  294. FIOCCHI C, Iliopoulos D
    Numbers Do Not Lie: The Dire Need for New Directions in IBD.
    J Crohns Colitis. 2022;16:1649-1650.
    >> Share

  295. KRUIS W, Siegmund B, Lesniakowski K, Simanenkov V, et al
    Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
    J Crohns Colitis. 2022;16:1714-1724.
    >> Share

  296. ZUO L, Li J, Zhang X, Geng Z, et al
    Aberrant Mesenteric Adipose Extracellular Matrix Remodelling is Involved in Adipocyte Dysfunction in Crohn's Disease: The Role of TLR-4-mediated Macrophages.
    J Crohns Colitis. 2022;16:1762-1776.
    >> Share

  297. BACHOUR SP, Shah RS, Rieder F, Qazi T, et al
    Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence.
    J Crohns Colitis. 2022;16:1696-1705.
    >> Share

  298. BERERA S, Ioannou SC, Morillo D, Mantero AMA, et al
    Combining Pentoxifylline With Vedolizumab for Crohn's Disease: Results of a Randomised, Placebo-controlled Pilot Study.
    J Crohns Colitis. 2022;16:1687-1695.
    >> Share

  299. KORI M, Zamir Y, Yermiyahu SO, Ainbinder I, et al
    The association of Inflammatory Bowel Disease with Celiac Disease and Celiac Autoimmunity in children and adults: A nationwide study from the epi-IIRN.
    J Crohns Colitis. 2022 Nov 17. pii: 6832168. doi: 10.1093.
    >> Share

  300. KUMAR L, Doherty G
    The Tortoise (Endoscopy-Driven Treatment) and the Hare (Prophylactic Treatment): Who Wins the Race to Beat Post-Operative Recurrence of Crohn's Disease?
    J Crohns Colitis. 2022 Nov 17:jjac165. doi: 10.1093.
    >> Share

  301. VAN DER DOES DE WILLEBOIS EML, Duijvestein M, Wasmann KA, D'Haens GRAM, et al
    Endoscopic Recurrence or Anastomotic Wound Healing Phenomenon after Ileocolic Resection for Crohn's Disease: The Challenges of Accurate Endoscopic Scoring.
    J Crohns Colitis. 2022 Nov 16:jjac175. doi: 10.1093.
    >> Share

  302. BATTAT R, Scherl EJ, Lukin D, Charilaou P, et al
    Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Nov 2. pii: 6794155. doi: 10.1093.
    >> Share

  303. ELLUL P, Schembri J, Baldacchino VA, Molnar T, et al
    Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease.
    J Crohns Colitis. 2022 Nov 2. pii: 6794125. doi: 10.1093.
    >> Share

  304. DUPONT-LUCAS C, Leroyer A, Ley D, Spyckerelle C, et al
    Increased risk of cancer and mortality in a large French population-based paediatric-onset inflammatory bowel disease retrospective cohort.
    J Crohns Colitis. 2022 Nov 1. pii: 6783208. doi: 10.1093.
    >> Share

  305. BOUCHER D, Barnich N
    Phage Therapy Against Adherent-invasive E. coli: Towards a Promising Treatment of Crohn's Disease Patients?
    J Crohns Colitis. 2022;16:1509-1510.
    >> Share

  306. DAL BUONO A, Faita F, Peyrin-Biroulet L, Danese S, et al
    Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment.
    J Crohns Colitis. 2022;16:1637-1646.
    >> Share

  307. DE VOOGD F, Bots S, Gecse K, Gilja OH, et al
    Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFalpha Treatment in Crohn's Disease.
    J Crohns Colitis. 2022;16:1598-1608.
    >> Share

  308. DUBINSKY V, Reshef L, Rabinowitz K, Wasserberg N, et al
    Escherichia coli Strains from Patients with Inflammatory Bowel Diseases have Disease-specific Genomic Adaptations.
    J Crohns Colitis. 2022;16:1584-1597.
    >> Share

  309. MONFORT-FERRE D, Caro A, Menacho M, Marti M, et al
    The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn's Disease.
    J Crohns Colitis. 2022;16:1571-1583.
    >> Share

  310. HU S, Mok J, Gowans M, Ong DEH, et al
    Oral Microbiome of Crohn's Disease Patients With and Without Oral Manifestations.
    J Crohns Colitis. 2022;16:1628-1636.
    >> Share

  311. KUMAR S, Parry T, Mallett S, Bhatnagar G, et al
    Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn's Disease: Experience from the METRIC Trial.
    J Crohns Colitis. 2022;16:1531-1539.
    >> Share

    October 2022
  312. BARRAU M, Duprat M, Veyrard P, Tournier Q, et al
    A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Oct 27. pii: 6775962. doi: 10.1093.
    >> Share

  313. LE HD, Pflaum T, Labrenz J, Sari S, et al
    Interobserver reliability of the Nancy index for ulcerative colitis: An assessment of the practicability and ease of use in a single-centre real-world setting.
    J Crohns Colitis. 2022 Oct 25. pii: 6773056. doi: 10.1093.
    >> Share

  314. TARGOWNIK L, Dubinsky MC, Steinwurz F, Bushmakin AG, et al
    Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1&2 and OCTAVE Sustain.
    J Crohns Colitis. 2022 Oct 22. pii: 6769962. doi: 10.1093.
    >> Share

  315. BYRNE MF, Panaccione R, East JE, Iacucci M, et al
    Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems.
    J Crohns Colitis. 2022 Oct 18. pii: 6762568. doi: 10.1093.
    >> Share


  316. Erratum to: Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study.
    J Crohns Colitis. 2022 Oct 17. pii: 6761987. doi: 10.1093.
    >> Share

  317. FOLLIN-ARBELET B, Milada SC, Hovde O, Jelsness-Jorgensen LP, et al
    Mortality in patients with Inflammatory Bowel Disease: Results from 30 years of follow-up in a Norwegian inception cohort (the IBSEN study).
    J Crohns Colitis. 2022 Oct 14. pii: 6761119. doi: 10.1093.
    >> Share

  318. VIEUJEAN S, Moens A, Hassid D, Rothfuss K, et al
    Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease - A case series.
    J Crohns Colitis. 2022 Oct 12. pii: 6759599. doi: 10.1093.
    >> Share

  319. OTERO-PINEIRO AM, Jia X, Pedersen KE, Hull T, et al
    Surgical Intervention is Effective for the Treatment of Crohn's related Rectovaginal Fistulas: Experience From A Tertiary Inflammatory Bowel Disease Practice.
    J Crohns Colitis. 2022 Oct 11. pii: 6758392. doi: 10.1093.
    >> Share

  320. BAHNAM P, Hanzel J, Ma C, Zou L, et al
    Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: Results from a systematic review of induction studies.
    J Crohns Colitis. 2022 Oct 11. pii: 6758390. doi: 10.1093.
    >> Share

  321. NYSTROM N, Prast-Nielsen S, Correia M, Globisch D, et al
    Mucosal and plasma metabolomes in new-onset paediatric inflammatory bowel disease: correlations with disease characteristics and plasma inflammation protein markers.
    J Crohns Colitis. 2022 Oct 11. pii: 6758389. doi: 10.1093.
    >> Share

  322. HANZEL J, Bossuyt P, Pittet V, Samaan M, et al
    Development of a Core Outcome Set for Real-World Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation (ECCO) Position Paper.
    J Crohns Colitis. 2022 Oct 3. pii: 6747109. doi: 10.1093.
    >> Share

    September 2022
  323. SCHOEFS E, Vermeire S, Ferrante M, Sabino J, et al
    What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study.
    J Crohns Colitis. 2022 Sep 27. pii: 6722595. doi: 10.1093.
    >> Share

  324. CROFT NM, de Ridder L, Griffiths AM, Hyams JS, et al
    Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents.
    J Crohns Colitis. 2022 Sep 21. pii: 6710188. doi: 10.1093.
    >> Share

  325. LOUIS E, Siegel CA, James B, Heidenreich S, et al
    Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study].
    J Crohns Colitis. 2022 Sep 20. pii: 6708291. doi: 10.1093.
    >> Share


  326. Erratum to: You Are What You Eat? Growing Evidence That Diet Influences the Risk of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Sep 19. pii: 6706938. doi: 10.1093.
    >> Share

  327. KURTI Z, Gonczi L, Lakatos L, Golovics P, et al
    Epidemiology, treatment strategy, natural disease course and surgical outcomes of patients with ulcerative colitis in Western Hungary - a population-based study between 2007 and 2018, data from the Veszprem County cohort.
    J Crohns Colitis. 2022 Sep 19. pii: 6705518. doi: 10.1093.
    >> Share

  328. DORN-RASMUSSEN M, Lo B, Zhao M, Kaplan GG, et al
    The incidence and prevalence of paediatric- and adult-onset inflammatory bowel disease in Denmark during a 37-year period - a nationwide cohort study (1980-2017).
    J Crohns Colitis. 2022 Sep 19. pii: 6705459. doi: 10.1093.
    >> Share

  329. WEWER MD, Langholz E, Munkholm P, Bendtsen F, et al
    Disease Activity Patterns of Inflammatory Bowel Disease - A Danish Nationwide Cohort Study 1995-2018.
    J Crohns Colitis. 2022 Sep 19. pii: 6705004. doi: 10.1093.
    >> Share

  330. SANDBORN WJ, D'Haens GR, Sands BE, Panaccione R, et al
    Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program.
    J Crohns Colitis. 2022 Sep 17. pii: 6702643. doi: 10.1093.
    >> Share

  331. MORTLOCK S, Lord A, Montgomery G, Zakrzewski M, et al
    An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis.
    J Crohns Colitis. 2022 Sep 16. pii: 6701957. doi: 10.1093.
    >> Share

  332. OLIVERA PA, Lasa JS, Zubiaurre I, Jairath V, et al
    Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Crohns Colitis. 2022 Sep 10. pii: 6695362. doi: 10.1093.
    >> Share

  333. DREWES AM
    Pain in Patients with Crohn's and Colitis: Can We Solve the Puzzle?
    J Crohns Colitis. 2022;16:1345-1346.
    >> Share

  334. MAGRO F, Estevinho MM
    COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives.
    J Crohns Colitis. 2022;16:1343-1344.
    >> Share

  335. SMITH PJ, Critchley L, Storey D, Gregg B, et al
    Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    J Crohns Colitis. 2022;16:1436-1446.
    >> Share

  336. XU C, Jiang W, Wang L, Mao X, et al
    Intestinal Ultrasound for Differentiating Fibrotic or Inflammatory Stenosis in Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2022;16:1493-1504.
    >> Share

  337. BURRELLO C, Strati F, Lattanzi G, Diaz-Basabe A, et al
    IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes.
    J Crohns Colitis. 2022;16:1461-1474.
    >> Share

  338. SAVELKOUL EHJ, Maas MHJ, Bourgonje AR, Crouwel F, et al
    Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease.
    J Crohns Colitis. 2022;16:1372-1379.
    >> Share

  339. SONNENBERG A, Genta RM
    Temporal changes in the histology of microscopic colitis.
    J Crohns Colitis. 2022;16:1415-1419.
    >> Share

  340. DOHERTY J, Morain NO, Stack R, Girod P, et al
    Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    J Crohns Colitis. 2022;16:1354-1362.
    >> Share

    August 2022
  341. VITALI R, Palone F, Armuzzi A, Fulci V, et al
    Proteomic analysis identifies three reliable biomarkers of intestinal inflammation in the stools of patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Aug 30. pii: 6679173. doi: 10.1093.
    >> Share

  342. JULIEN C, Anakok E, Treton X, Nachury M, et al
    Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort.
    J Crohns Colitis. 2022;16:1211-1221.
    >> Share

  343. BRETON J, Tanes C, Tu V, Albenberg L, et al
    A Microbial Signature for Paediatric Perianal Crohn's Disease.
    J Crohns Colitis. 2022;16:1281-1292.
    >> Share

  344. SUDHAKAR P, Alsoud D, Wellens J, Verstockt S, et al
    Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.
    J Crohns Colitis. 2022;16:1306-1320.
    >> Share

  345. NGOLLO M, Perez K, Hammoudi N, Gorelik Y, et al
    Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease.
    J Crohns Colitis. 2022;16:1269-1280.
    >> Share

  346. KALLA R, Adams AT, Nowak JK, Bergemalm D, et al
    Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome.
    J Crohns Colitis. 2022 Aug 27. pii: 6677995. doi: 10.1093.
    >> Share

  347. LOFTUS EV, Vermeire S, Feagan BG, Le Brun FO, et al
    Corticosteroid-sparing Effects of Filgotinib in Moderate to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    J Crohns Colitis. 2022 Aug 25. pii: 6675518. doi: 10.1093.
    >> Share

  348. NARULA N, Merat S, Liu D, Pugatch D, et al
    Time to endorse a sensitive method for scoring endoscopic activity of ulcerative colitis in clinical research.
    J Crohns Colitis. 2022 Aug 24. pii: 6674697. doi: 10.1093.
    >> Share

  349. JOUSTRA V, Hageman IL, Satsangi J, Adams A, et al
    Systematic Review and Meta-analysis of Peripheral Blood DNA methylation studies in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Aug 23. pii: 6674036. doi: 10.1093.
    >> Share


  350. Corrigendum to: P169 Vitamin D levels are inversely associated with inflammation in pediatric Inflammatory Bowel Disease patients.
    J Crohns Colitis. 2022 Aug 22. pii: 6673037. doi: 10.1093.
    >> Share

  351. LIN V, Gogenur S, Pachler F, Fransgaard T, et al
    Risk prediction for complications in Inflammatory Bowel Disease surgery: External validation of the American College of Surgeons' National Surgical Quality Improvement Program Surgical Risk Calculator.
    J Crohns Colitis. 2022 Aug 17. pii: 6668838. doi: 10.1093.
    >> Share

  352. HONAP S, Irving PM, Samaan MA
    Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis.
    J Crohns Colitis. 2022 Aug 12. pii: 6663939. doi: 10.1093.
    >> Share

  353. CARON B, D'Amico F, Jairath V, Netter P, et al
    Available methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs.
    J Crohns Colitis. 2022 Aug 11. pii: 6661406. doi: 10.1093.
    >> Share

  354. HARVEY PR, Coupland B, Mytton J, De Silva S, et al
    Venous thromboembolism following discharge from hospital in patients admitted for inflammatory bowel disease.
    J Crohns Colitis. 2022 Aug 10. pii: 6660709. doi: 10.1093.
    >> Share

  355. TORRES J, Gomes C, Jensen C, Agrawal M, et al
    Risk factors for developing Inflammatory Bowel Disease Within and Across Families with Family History of IBD.
    J Crohns Colitis. 2022 Aug 9. pii: 6659033. doi: 10.1093.
    >> Share

  356. LIU X, Ren X, Zhou L, Liu K, et al
    Tollip Orchestrates Macrophage Polarization to Alleviate Intestinal Mucosal Inflammation.
    J Crohns Colitis. 2022;16:1151-1167.
    >> Share

  357. NARULA N, Pray C, Wong ECL, Colombel JF, et al
    Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD].
    J Crohns Colitis. 2022;16:1011-1019.
    >> Share

  358. HUANG L, Qian W, Xu Y, Guo Z, et al
    Mesenteric Adipose Tissue Contributes to Intestinal Fibrosis in Crohn's Disease Through the ATX-LPA Axis.
    J Crohns Colitis. 2022;16:1124-1139.
    >> Share

  359. BARREIRO-DE ACOSTA M, Riestra S, Calafat M, Soto MP, et al
    Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU.
    J Crohns Colitis. 2022;16:1049-1058.
    >> Share

  360. FIERENS L, Liefferinckx C, Hoefkens E, Lobaton T, et al
    Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
    J Crohns Colitis. 2022;16:1059-1069.
    >> Share

  361. ABD EL AZIZ MA, Abdalla S, Calini G, Saeed H, et al
    Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
    J Crohns Colitis. 2022;16:1079-1088.
    >> Share

  362. GAO H, He Q, Xu C, Pang Z, et al
    The Development and Validation of Anti-paratuberculosis-nocardia Polypeptide Antibody [Anti-pTNP] for the Diagnosis of Crohn's Disease.
    J Crohns Colitis. 2022;16:1110-1123.
    >> Share

  363. CROUWEL F, Buiter HJC, de Boer NK
    The Thiopurine Tale: An Unexpected Journey.
    J Crohns Colitis. 2022;16:1177-1183.
    >> Share

  364. DOUADI C, Vazeille E, Chambon C, Hebraud M, et al
    Anti-TNF Agents Restrict Adherent-invasive Escherichia coli Replication Within Macrophages Through Modulation of Chitinase 3-like 1 in Patients with Crohn's Disease.
    J Crohns Colitis. 2022;16:1140-1150.
    >> Share

  365. ATIA O, Kang B, Orlansky-Meyer E, Ledder O, et al
    Existing Prediction Models of Disease Course in Paediatric Crohn's Disease Are Poorly Replicated in a Prospective Inception Cohort.
    J Crohns Colitis. 2022;16:1039-1048.
    >> Share

    July 2022
  366. DIRVANSKYTE P, Gurram B, Bolton C, Warner N, et al
    Chromosomal numeric aberrations and rare copy number variation in patients with inflammatory bowel disease.
    J Crohns Colitis. 2022 Jul 30. pii: 6652479. doi: 10.1093.
    >> Share

  367. WONG D, Matini L, Kormilitzin A, Kantschuster R, et al
    Patient Reported Outcomes: the ICHOM Standard Set for inflammatory bowel disease in real life practice helps quantify deficits in current care.
    J Crohns Colitis. 2022 Jul 22. pii: 6648780. doi: 10.1093.
    >> Share

  368. YARUR AJ
    Intestinal Tissue Levels of Anti-Tumour Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases: Are We Looking in The Right Place at The Right Time?
    J Crohns Colitis. 2022;16:869-870.
    >> Share

  369. MAGRO F, Sabino J, Rosini F, Tripathi M, et al
    ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology.
    J Crohns Colitis. 2022;16:876-883.
    >> Share

  370. SENSI B, Khan J, Warusavitarne J, Nardi A, et al
    Long-term Oncological Outcome of Segmental Versus Extended Colectomy for Colorectal Cancer in Crohn's Disease: Results from an International Multicentre Study.
    J Crohns Colitis. 2022;16:954-962.
    >> Share

  371. CHAKRABORTY R, Maltz MR, Del Castillo D, Tandel PN, et al
    Selective Targeting of Tumour Necrosis Factor Receptor 1 Induces Stable Protection from Crohn's-Like Ileitis in TNFDeltaARE Mice.
    J Crohns Colitis. 2022;16:978-991.
    >> Share

  372. PETERS V, Bolte L, Schuttert EM, Andreu-Sanchez S, et al
    Western and Carnivorous Dietary Patterns are Associated with Greater Likelihood of IBD Development in a Large Prospective Population-based Cohort.
    J Crohns Colitis. 2022;16:931-939.
    >> Share

  373. CARON B, Sandborn WJ, Panaccione R, Schreiber S, et al
    Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review.
    J Crohns Colitis. 2022;16:922-930.
    >> Share

  374. WALSHE M, Nayeri S, Ji J, Hernandez-Rocha C, et al
    A Role for CXCR3 Ligands as Biomarkers of Post-Operative Crohn's Disease Recurrence.
    J Crohns Colitis. 2022;16:900-910.
    >> Share

  375. SWAMINATHAN A, Borichevsky GM, Edwards TS, Hirschfeld E, et al
    Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jul 8. pii: 6634254. doi: 10.1093.
    >> Share

    June 2022
  376. ZHANG R, Lauwers GY, Choi WT
    Increased Risk of Non-Conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jun 30. pii: 6623587. doi: 10.1093.
    >> Share


  377. Corrigendum to: ECCO CONFER Investigators, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series.
    J Crohns Colitis. 2022 Jun 25. pii: 6617788. doi: 10.1093.
    >> Share

  378. HONAP S, Meade S, Spencer A, Pavlidis P, et al
    Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment.
    J Crohns Colitis. 2022;16:822-834.
    >> Share

  379. VIGORITA V, Cano-Valderrama O, Celentano V, Vinci D, et al
    Inflammatory Bowel Diseases Benefit from Enhanced Recovery After Surgery [ERAS] Protocol: A Systematic Review with Practical Implications.
    J Crohns Colitis. 2022;16:845-851.
    >> Share

  380. ATIA O, Harel S, Ledderman N, Greenfeld S, et al
    Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN.
    J Crohns Colitis. 2022;16:786-795.
    >> Share

  381. ATIA O, Orlanski-Meyer E, Lujan R, Ledderman N, et al
    Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics-A Nationwide Study From the Epi-IIRN.
    J Crohns Colitis. 2022;16:778-785.
    >> Share

  382. ALMRADI A, Sedano R, Hogan M, Zou GY, et al
    Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials.
    J Crohns Colitis. 2022;16:717-736.
    >> Share

  383. D'HAENS G, Danese S, Davies M, Watanabe M, et al
    A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease.
    J Crohns Colitis. 2022;16:746-756.
    >> Share

  384. ATTAUABI M, Dahlerup JF, Poulsen A, Hansen MR, et al
    Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases - A Danish Prospective Population-Based Cohort Study with Individual-Level Data.
    J Crohns Colitis. 2022;16:757-767.
    >> Share

  385. VAN RIJN KL, Meima-van Praag EM, Bossuyt PM, D'Haens GR, et al
    Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients.
    J Crohns Colitis. 2022;16:708-716.
    >> Share

  386. REENAERS C, Louis E
    Progressing Towards the Implementation of a Treat-To-Target Strategy in Perianal Crohn's Disease.
    J Crohns Colitis. 2022;16:693-694.
    >> Share

  387. ILVEMARK JFKF, Wilkens R, Thielsen P, Dige A, et al
    Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalized patients with severe ulcerative colitis.
    J Crohns Colitis. 2022 Jun 13. pii: 6607631. doi: 10.1093.
    >> Share

  388. KIM KO, Kim EY, Lee YJ, Lee HS, et al
    Efficacy, safety and tolerability of oral sulfate tablet for bowel preparation in patients with inflammatory bowel disease: Multicenter randomized controlled study.
    J Crohns Colitis. 2022 Jun 11. pii: 6605993. doi: 10.1093.
    >> Share

  389. JAGT JZ, Verburgt CM, de Vries R, de Boer NKH, et al
    Faecal metabolomics in paediatric inflammatory bowel disease: a systematic review.
    J Crohns Colitis. 2022 Jun 9. pii: 6605030. doi: 10.1093.
    >> Share

  390. CLARKSTON K, Karns R, Jegga AG, Sharma M, et al
    Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.
    J Crohns Colitis. 2022 Jun 4. pii: 6602063. doi: 10.1093.
    >> Share

    May 2022
  391. TORRENTE F, Meade S, Benchimol EI, de Ridder L, et al
    Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel.
    J Crohns Colitis. 2022 May 24. pii: 6591364. doi: 10.1093.
    >> Share

  392. DANESE S, Peyrin-Biroulet L
    Evolution of IL-23 Blockade in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022;16.
    >> Share

  393. SEWELL GW, Kaser A
    Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention.
    J Crohns Colitis. 2022;16.
    >> Share

  394. PARIGI TL, Iacucci M, Ghosh S
    Blockade of IL-23: What is in the Pipeline?
    J Crohns Colitis. 2022;16.
    >> Share

  395. D'AMICO F, Peyrin-Biroulet L, Danese S
    Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
    J Crohns Colitis. 2022;16.
    >> Share

  396. MCDONALD BD, Dyer EC, Rubin DT
    IL-23 Monoclonal Antibodies for IBD: So Many, So Different?
    J Crohns Colitis. 2022;16.
    >> Share

  397. VALENTI M, Narcisi A, Pavia G, Gargiulo L, et al
    What Can IBD Specialists Learn from IL-23 Trials in Dermatology?
    J Crohns Colitis. 2022;16.
    >> Share

  398. ATREYA R, Neurath MF
    IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.
    J Crohns Colitis. 2022;16.
    >> Share

  399. GOTTLIEB ZS, Sands BE
    Personalised Medicine with IL-23 Blockers: Myth or Reality?
    J Crohns Colitis. 2022;16.
    >> Share

  400. CALVET X, Panes J, Gallardo-Escudero J, de la Cuadra-Grande A, et al
    Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain.
    J Crohns Colitis. 2022 May 11. pii: 6584605. doi: 10.1093.
    >> Share

  401. ROGLER G
    No Need to Scope? Monitoring of Treatment Response in IBD Patients by Transabdominal Ultrasound.
    J Crohns Colitis. 2022;16:521-522.
    >> Share

  402. KAKUTA Y, Iwaki H, Umeno J, Kawai Y, et al
    Crohn's Disease and Early Exposure to Thiopurines are Independent Risk Factors for Mosaic Chromosomal Alterations in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2022;16:643-655.
    >> Share

  403. VERBURGT CM, Dunn KA, Van Limbergen JE
    Dietary Therapy Reduces Pro-inflammatory Microbiome Features in Paediatric Crohn's Disease.
    J Crohns Colitis. 2022;16:682-684.
    >> Share

  404. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease.
    J Crohns Colitis. 2022;16:616-624.
    >> Share

  405. BOTS S, De Voogd F, De Jong M, Ligtvoet V, et al
    Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm.
    J Crohns Colitis. 2022;16:606-615.
    >> Share

  406. DAOUD ND, Hashash JG, Picco MF, Farraye FA, et al
    Faecal Calprotectin from Ileostomy Output Is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn's Disease.
    J Crohns Colitis. 2022;16:601-605.
    >> Share

  407. KUCHARZIK T, Tielbeek J, Carter D, Taylor SA, et al
    ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022;16:523-543.
    >> Share

  408. SUN TY, Li YQ, Zhao FQ, Sun HM, et al
    MiR-1-3p and MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon.
    J Crohns Colitis. 2022;16:656-667.
    >> Share

  409. ALSOUD D, De Hertogh G, Compernolle G, Tops S, et al
    Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.
    J Crohns Colitis. 2022 May 9. pii: 6582859. doi: 10.1093.
    >> Share

  410. STODTMANN S, Chen MJ, Siovitz L, Bereswill M, et al
    Bridging Fixed Dose to Body Weight-Based Regimen of Adalimumab in Pediatric Ulcerative Colitis Using a Pharmacometric Modeling Approach: Case Study with the Phase 3 ENVISION I Trial.
    J Crohns Colitis. 2022 May 8. pii: 6582407. doi: 10.1093.
    >> Share

  411. SHRESTHA S, Brand JS, Jaras J, Schoultz I, et al
    Association between inflammatory bowel disease and spondyloarthritis: findings from a nationwide study in Sweden.
    J Crohns Colitis. 2022 May 5. pii: 6581445. doi: 10.1093.
    >> Share

  412. WONG C, van Oostrom J, Bossuyt P, Pittet V, et al
    A narrative systematic review and categorisation of outcomes in Inflammatory Bowel Disease to inform a Core Outcome Set for real-world evidence.
    J Crohns Colitis. 2022 May 5. pii: 6580715. doi: 10.1093.
    >> Share

  413. POULLENOT F, Amiot A, Nachury M, Viennot S, et al
    Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
    J Crohns Colitis. 2022 May 5. pii: 6580681. doi: 10.1093.
    >> Share

    April 2022
  414. DE GALAN C, Truyens M, Peeters H, Mesonero Gismero F, et al
    The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study.
    J Crohns Colitis. 2022 Apr 20. pii: 6571450. doi: 10.1093.
    >> Share

  415. FERNANDEZ ME, Nazar FN, Moine LB, Jaime CE, et al
    Network analysis of inflammatory bowel disease research: towards the interactome.
    J Crohns Colitis. 2022 Apr 19. pii: 6570854. doi: 10.1093.
    >> Share

  416. UNGARO RC, Chou B, Mo J, Ursos L, et al
    Impact of COVID-19 on Healthcare Resource Utilization among Patients with Inflammatory Bowel Disease in the USA.
    J Crohns Colitis. 2022 Apr 9. pii: 6565722. doi: 10.1093.
    >> Share

  417. DONG C, Chan SSM, Jantchou P, Racine A, et al
    Meat intake is associated with a higher risk of ulcerative colitis in a large European prospective cohort study.
    J Crohns Colitis. 2022 Apr 9. pii: 6565743. doi: 10.1093.
    >> Share

  418. DOLINGER MT, Rolfes P, Spencer E, Stoffels G, et al
    Outcomes of Children With Inflammatory Bowel Disease Who Develop Anti-Tumor Necrosis Factor Induced Skin Reactions.
    J Crohns Colitis. 2022 Apr 7. pii: 6564796. doi: 10.1093.
    >> Share

  419. HARDY PY, Fikri J, Libbrecht D, Louis E, et al
    Pain characteristics in patients with inflammatory bowel disease: A monocentric cross-sectional study.
    J Crohns Colitis. 2022 Apr 4. pii: 6563361. doi: 10.1093.
    >> Share

  420. CHAPARRO M, Kunovsky L, Aguas M, Livne M, et al
    Surgery Due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study).
    J Crohns Colitis. 2022 Apr 4. pii: 6563346. doi: 10.1093.
    >> Share

  421. COLLEN LV, Kim DY, Field M, Okoroafor I, et al
    Clinical Phenotypes and Outcomes in Monogenic versus Non-Monogenic Very Early Onset Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Apr 2. pii: 6562761. doi: 10.1093.
    >> Share

    March 2022
  422. CERNA K, Duricova D, Hindos M, Hindos HJ, et al
    Cellular and humoral immune responses to SARS-CoV-2 vaccination in inflammatory bowel disease patients.
    J Crohns Colitis. 2022 Mar 31. pii: 6561818. doi: 10.1093.
    >> Share

  423. KHAN N, Trivedi C, Aberra F, Pernes T, et al
    Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Mar 29. pii: 6555677. doi: 10.1093.
    >> Share

  424. DING NS, Tassone D, Al-Bakir I, Wu K, et al
    Systematic review: The impact and importance of body composition in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Mar 24. pii: 6553364. doi: 10.1093.
    >> Share

  425. MORTENSEN JH, Sinkeviciute D, Manon-Jensen T, Domislovic V, et al
    A specific calprotectin neo-epitope (CPa9-HNE) in serum from inflammatory bowel disease patients is associated with neutrophil activity and endoscopic severity.
    J Crohns Colitis. 2022 Mar 19. pii: 6550845. doi: 10.1093.
    >> Share

  426. HYAMS JS, Turner D, Cohen SA, Szakos E, et al
    Pharmacokinetics, Safety, and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
    J Crohns Colitis. 2022 Mar 17. pii: 6550285. doi: 10.1093.
    >> Share

  427. VELOSA M, Hochner H, Yerushalmi B, Harel S, et al
    Pre and perinatal factors predicting Inflammatory Bowel Disease - a population-based study with fifty years follow-up.
    J Crohns Colitis. 2022 Mar 17. pii: 6550290. doi: 10.1093.
    >> Share

  428. SANDBORN WJ, Lewis JD, Panes J, Loftus EV, et al
    Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.
    J Crohns Colitis. 2022;16:444-451.
    >> Share

  429. SUAU R, Pardina E, Domenech E, Loren V, et al
    The Complex Relationship Between Microbiota, Immune Response and Creeping Fat in Crohn's Disease.
    J Crohns Colitis. 2022;16:472-489.
    >> Share

  430. BLE A, Renzulli C, Cenci F, Grimaldi M, et al
    The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2022;16:490-499.
    >> Share

  431. PHILLIPS F, Verstockt B, Sladek M, de Boer N, et al
    Orofacial Granulomatosis Associated with Crohn's Disease: a Multicentre Case Series.
    J Crohns Colitis. 2022;16:430-435.
    >> Share

  432. NGUYEN NH, Picetti D, Dulai PS, Jairath V, et al
    Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2022;16:398-413.
    >> Share

  433. VIEUJEAN S, Loly JP, Boutaffala L, Meunier P, et al
    Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: A Phase I-II Clinical Study.
    J Crohns Colitis. 2022;16:506-510.
    >> Share

  434. CHANCHLANI N, Lin S, Chee D, Hamilton B, et al
    Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    J Crohns Colitis. 2022;16:389-397.
    >> Share

  435. LEVER G, Chipeta H, Glanville T, Selinger C, et al
    Perineal Outcomes After Delivery in 179 Mothers with Inflammatory Bowel Disease Compared to 31 258 Controls: A Single-Centre Cohort Study.
    J Crohns Colitis. 2022;16:511-514.
    >> Share

  436. FEAKINS R, Torres J, Borralho-Nunes P, Burisch J, et al
    ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022;16:343-368.
    >> Share

  437. ROBERTSON AR, Webster KL
    Disease activity in the final years of life for patients with longstanding Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Mar 7. pii: 6543872. doi: 10.1093.
    >> Share

  438. ABREU MT, Rowbotham DS, Danese S, Sandborn WJ, et al
    Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    J Crohns Colitis. 2022 Mar 3. pii: 6542054. doi: 10.1093.
    >> Share

  439. SCIBERRAS M, Karmiris K, Nascimento C, Tabone T, et al
    Mental health, work presenteeism and exercise in inflammatory bowel disease.
    J Crohns Colitis. 2022 Mar 3. pii: 6542057. doi: 10.1093.
    >> Share

  440. BURGESS CJ, Schnier C, Wood R, Henderson P, et al
    Prematurity, delivery method and infant feeding type are not associated with paediatric-onset inflammatory bowel disease risk: A Scottish retrospective birth cohort study.
    J Crohns Colitis. 2022 Mar 1. pii: 6540489. doi: 10.1093.
    >> Share

    February 2022
  441. COTTRON C, Treton X, Altwegg R, Reenaers C, et al
    How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study.
    J Crohns Colitis. 2022 Feb 26. pii: 6537448. doi: 10.1093.
    >> Share

  442. NOWAK JK, Adams AT, Kalla R, Lindstrom JC, et al
    Characterization of the circulating transcriptomic landscape in inflammatory bowel disease provides evidence for dysregulation of multiple transcription factors including NFE2, SPI1, CEBPB, and IRF2.
    J Crohns Colitis. 2022 Feb 25. pii: 6536718. doi: 10.1093.
    >> Share

  443. TRACY M, Khalili H
    You Are What You Eat? Growing Evidence That Diet Influences the Risk of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Feb 23. pii: 6534662. doi: 10.1093.
    >> Share

  444. BISLENGHI G, Sucameli F, Fieuws S, Ferrante M, et al
    Non-conventional Versus Conventional Strictureplasties for Crohn's Disease. A Systematic Review and Meta-analysis of Treatment Outcomes.
    J Crohns Colitis. 2022;16:319-330.
    >> Share

  445. DHALIWAL J, Carroll MW, deBruyn JC, Ricciuto A, et al
    The Phenotypic Spectrum of New-onset IBD in Canadian Children of South Asian Ethnicity: A Prospective Multi-Centre Comparative Study.
    J Crohns Colitis. 2022;16:216-223.
    >> Share

  446. CLEMENT F, Nougarede A, Combe S, Kermarrec F, et al
    Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2022;16:286-300.
    >> Share

  447. ELDRIDGE F, Raine T
    Understanding and Addressing the Psychological Burden of IBD.
    J Crohns Colitis. 2022;16:177-178.
    >> Share

  448. LAUDISI F, Stolfi C, Bevivino G, Maresca C, et al
    GATA6 Deficiency Leads to Epithelial Barrier Dysfunction and Enhances Susceptibility to Gut Inflammation.
    J Crohns Colitis. 2022;16:301-311.
    >> Share

  449. BACSUR P, Farkas K, Molnar T
    Area of the IBD Disk Correlated Strongly with Disease Activity Compared with the Conventionally Used IBD Disk Score.
    J Crohns Colitis. 2022;16:336.
    >> Share

  450. OSTROWSKI S, Croft A
    Viral enteric infections in acute severe ulcerative colitis.
    J Crohns Colitis. 2022 Feb 15. pii: 6528523. doi: 10.1093.
    >> Share

  451. CROFT A, Lord A, Radford-Smith G
    Markers of systemic inflammation in acute attacks of ulcerative colitis: What level of C-reactive protein constitutes severe colitis?
    J Crohns Colitis. 2022 Feb 11. pii: 6527048. doi: 10.1093.
    >> Share

  452. MOOKHOEK A, Haasnoot ML, Bredenoord AJ, Ma C, et al
    The clinical significance of eosinophils in ulcerative colitis: a systematic review.
    J Crohns Colitis. 2022 Feb 9. pii: 6524727. doi: 10.1093.
    >> Share

  453. HUA X, Lopes EW, Burke KE, Ananthakrishnan AN, et al
    Smoking behavior changes after diagnosis of inflammatory bowel disease and risk of all-cause mortality.
    J Crohns Colitis. 2022 Feb 1. pii: 6518234. doi: 10.1093.
    >> Share

    January 2022
  454. VERMEIRE S, D'Haens G, Baert F, Danese S, et al
    Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
    J Crohns Colitis. 2022;16:27-38.
    >> Share

  455. ALBSHESH A, Eder P, Ribaldone DG, Oldenburg B, et al
    Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2022;16:91-97.
    >> Share

  456. ZILBAUER M, Heuschkel R
    Disease Prognostic Biomarkers in Inflammatory Bowel Diseases-A Reality Check.
    J Crohns Colitis. 2022;16:162-165.
    >> Share

  457. FERREIRA JPS, de Mascarenhas Saraiva MJDQEC, Afonso JPL, Ribeiro TFC, et al
    Identification of Ulcers and Erosions by the Novel Pillcam Crohn's Capsule Using a Convolutional Neural Network: A Multicentre Pilot Study.
    J Crohns Colitis. 2022;16:169-172.
    >> Share

  458. HELWIG U, Fischer I, Hammer L, Kolterer S, et al
    Transmural Response and Transmural Healing Defined by Intestinal Ultrasound: New Potential Therapeutic Targets?
    J Crohns Colitis. 2022;16:57-67.
    >> Share

  459. KABIR M, Thomas-Gibson S, Hart AL, Wilson A, et al
    Perception of Cancer Risk and Management Practice for Colitis-associated Dysplasia Is Influenced by Colonoscopy Experience and Workplace Affiliation: Results of an International Clinician Survey.
    J Crohns Colitis. 2022;16:39-48.
    >> Share

  460. FULFORTH J, Gearry R
    Inequitable Access to IBD Therapies Extends Beyond Developing Nations.
    J Crohns Colitis. 2022;16:173-174.
    >> Share

  461. HANZEL J, Jairath V
    A TIGER Among Endoscopic Indices in Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jan 21. pii: 6513472. doi: 10.1093.
    >> Share

  462. NUNEZ F P, Quera R, Bay C, Castro F, et al
    Drug-induced liver injury used in the treatment of Inflammatory Bowel Disease.
    J Crohns Colitis. 2022 Jan 19. pii: 6511546. doi: 10.1093.
    >> Share

  463. ELLUL P, Reves J, Abreu B, Chaparro M, et al
    Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey.
    J Crohns Colitis. 2022 Jan 17. pii: 6509060. doi: 10.1093.
    >> Share

  464. JUZENAS S, Hubenthal M, Lindqvist CM, Kruse R, et al
    Detailed transcriptional landscape of peripheral blood points to increased neutrophil activation in treatment-naive inflammatory bowel disease.
    J Crohns Colitis. 2022 Jan 11. pii: 6503823. doi: 10.1093.
    >> Share

  465. DE BOER NK, van Lookeren FL, Tack GJ
    The launch of an online national multidisciplinary expert panel for inflammatory bowel disease.
    J Crohns Colitis. 2022 Jan 6. pii: 6499222. doi: 10.1093.
    >> Share

  466. HERNANDEZ-ROCHA C, Nayeri S, Turpin W, Steel M, et al
    Combined histo-endoscopic remission but not endoscopic healing alone in ulcerative colitis is associated with a mucosal transcriptional profile resembling healthy mucosa.
    J Crohns Colitis. 2022 Jan 6. pii: 6499459. doi: 10.1093.
    >> Share

  467. TORRENTE F, Hansen R
    Venous Thromboembolism in Children with Inflammatory Bowel Disease: When is the Right Time for Thromboprophylaxis?
    J Crohns Colitis. 2022 Jan 3. pii: 6494523. doi: 10.1093.
    >> Share

    December 2021
  468. VENTRESS E, Young D, Rahmany S, Harris C, et al
    Transitioning from intRavenous to subcutAneous VEdolizumab in patients with infLammatory bowEl diSeaSe (TRAVELESS).
    J Crohns Colitis. 2021 Dec 22. pii: 6478741. doi: 10.1093.
    >> Share

  469. GIANNINI EG, Demarzo MG, Bodini G
    Elevated Adherence to Vaccination Against SARS-CoV-2 Among Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021;15:2142-2143.
    >> Share

  470. GOLDBERG R, Clough JN, Roberts LB, Sanchez J, et al
    A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.
    J Crohns Colitis. 2021;15:2054-2065.
    >> Share

  471. RYVCHIN R, Dubinsky V, Rabinowitz K, Wasserberg N, et al
    Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:2066-2077.
    >> Share

  472. SPALINGER MR, Schwarzfischer M, Niechcial A, Atrott K, et al
    Loss of PTPN22 Promotes Intestinal Inflammation by Compromising Granulocyte-mediated Antibacterial Defence.
    J Crohns Colitis. 2021;15:2118-2130.
    >> Share

  473. DERIKX LAAP, Dolby HW, Plevris N, Lucaciu L, et al
    Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naive SB5 Observational Cohorts.
    J Crohns Colitis. 2021;15:2011-2021.
    >> Share

  474. FERRANTE M, Feagan BG, Panes J, Baert F, et al
    Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    J Crohns Colitis. 2021;15:2001-2010.
    >> Share

  475. NI H, Chen Y, Xia W, Wang C, et al
    SATB2 Defect Promotes Colitis and Colitis-associated Colorectal Cancer by Impairing Cl-/HCO3- Exchange and Homeostasis of Gut Microbiota.
    J Crohns Colitis. 2021;15:2088-2102.
    >> Share

  476. WANG L, Zhang N, Han D, Su P, et al
    MTDH Promotes Intestinal Inflammation by Positively Regulating TLR Signalling.
    J Crohns Colitis. 2021;15:2103-2117.
    >> Share

  477. CASADO-BEDMAR M, Viennois E
    microRNA and gut microbiota: Tiny but mighty - Novel insights of their crosstalk in inflammatory bowel disease pathogenesis and therapeutics.
    J Crohns Colitis. 2021 Dec 16. pii: 6464304. doi: 10.1093.
    >> Share

  478. CALAFAT M, Manosa M, Ricart E, Nos P, et al
    Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
    J Crohns Colitis. 2021 Dec 3. pii: 6448705. doi: 10.1093.
    >> Share

  479. FESTA S, Zerboni G, Derikx LAAP, Ribaldone DG, et al
    Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2021 Dec 1. pii: 6447455. doi: 10.1093.
    >> Share

    November 2021
  480. GORDON IO, Abushamma S, Kurowski JA, Holubar SD, et al
    Pediatric Ulcerative Colitis Is A Fibrotic Disease And Linked With Chronicity Of Inflammation.
    J Crohns Colitis. 2021 Nov 29. pii: 6445941. doi: 10.1093.
    >> Share

  481. BAR-YOSEPH H, Blatt A, Gerassy S, Pressman S, et al
    Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Nov 24. pii: 6438514. doi: 10.1093.
    >> Share

  482. PRENTICE RE, Ross AL, Flanagan EK
    Management of Pregnant Women with Inflammatory Bowel Disease and COVID-19-Balancing Risks of Delayed Treatment Recommencement.
    J Crohns Colitis. 2021 Nov 23. pii: 6433604. doi: 10.1093.
    >> Share

  483. PAPAEFTHYMIOU A, Potamianos S, Goulas A, Doulberis M, et al
    Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.
    J Crohns Colitis. 2021 Nov 22. pii: 6433262. doi: 10.1093.
    >> Share

  484. ATIA O, Orlanski-Meyer E, Lujan R, Ledderman N, et al
    Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN.
    J Crohns Colitis. 2021 Nov 20. pii: 6432553. doi: 10.1093.
    >> Share

  485. BACSUR P, Farkas K, Molnar T
    Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Nov 18. pii: 6430840. doi: 10.1093.
    >> Share

  486. GUPTA R, MacIsaac M, Wright EK
    Sleeve gastrectomy in patients with inflammatory bowel disease is not associated with worsening disease.
    J Crohns Colitis. 2021 Nov 17. pii: 6430439. doi: 10.1093.
    >> Share

  487. D'AMICO F, Magro F, Peyrin-Biroulet L, Danese S, et al
    Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis.
    J Crohns Colitis. 2021 Nov 16. pii: 6429427. doi: 10.1093.
    >> Share

  488. NICHOLSON MR, Alexander E, Ballal S, Davidovics Z, et al
    Efficacy and Outcomes of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Nov 12. pii: 6425925. doi: 10.1093.
    >> Share

  489. VAN ERP LW, Neijenhuis MK, Heida W, Derwig J, et al
    Improving care for recently diagnosed inflammatory bowel disease patients: Lessons learned from a patient-centred, mixed-method study.
    J Crohns Colitis. 2021 Nov 10. pii: 6425110. doi: 10.1093.
    >> Share

  490. CHARPY F, Altwegg R, Debourdeau A
    Disseminated tuberculosis in a patient treated with tofacitinib for ulcerative colitis.
    J Crohns Colitis. 2021 Nov 9. pii: 6424411. doi: 10.1093.
    >> Share

  491. AGRAWAL M, Zhang X, Brenner EJ, Ungaro RC, et al
    The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    J Crohns Colitis. 2021;15:1877-1884.
    >> Share

  492. WETWITTAYAKHLANG P, Lakatos PL
    Comforting Data on the Incidence of Rectal Cancer After Subtotal Colectomy in IBD: The Risk Is Low, Yet Surveillance Matters!
    J Crohns Colitis. 2021;15:1783-1784.
    >> Share

  493. ROSH JR, Turner D, Griffiths A, Cohen SA, et al
    Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
    J Crohns Colitis. 2021;15:1931-1942.
    >> Share

  494. REZAZADEH ARDABILI A, Goudkade D, Wintjens D, Romberg-Camps M, et al
    Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease.
    J Crohns Colitis. 2021;15:1885-1897.
    >> Share

  495. SELIN KA, Hedin CRH, Villablanca EJ
    Immunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:1959-1973.
    >> Share

  496. NAFTALI T, Bar-Lev Schleider L, Almog S, Meiri D, et al
    Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.
    J Crohns Colitis. 2021;15:1799-1806.
    >> Share

  497. LUO J, Xu Z, Noordam R, van Heemst D, et al
    Depression and Inflammatory Bowel Disease: A Bidirectional two-sample Mendelian Randomization Study.
    J Crohns Colitis. 2021 Nov 5. pii: 6421452. doi: 10.1093.
    >> Share

    October 2021
  498. GARRIDO I, Lopes S, Macedo G
    "Safety of COVID-19 vaccination in inflammatory bowel disease patients on biologic therapy".
    J Crohns Colitis. 2021 Oct 30. pii: 6414658. doi: 10.1093.
    >> Share

  499. LIMA SF, Longman RS
    Eating for Two: Diet and the Microbiome in Ulcerative Colitis.
    J Crohns Colitis. 2021 Oct 27. pii: 6412629. doi: 10.1093.
    >> Share

  500. FRIEDMAN S, Zegers FD, Jolving LR, Nielsen J, et al
    Postpartum surgical complications in women with inflammatory bowel disease after caesarian section: A Danish nationwide cohort study.
    J Crohns Colitis. 2021 Oct 27. pii: 6412778. doi: 10.1093.
    >> Share

  501. CHARKAOUI M, Hajage D, Tubach F, Laurent B, et al
    Impact of anti-tumor necrosis factor agents on the risk of colorectal cancer in patients with ulcerative colitis: nationwide French cohort study.
    J Crohns Colitis. 2021 Oct 18. pii: 6399096. doi: 10.1093.
    >> Share

  502. RAINE T, Bonovas S, Burisch J, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.
    J Crohns Colitis. 2021 Oct 12. pii: 6390052. doi: 10.1093.
    >> Share

  503. SPINELLI A, Bonovas S, Burisch J, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.
    J Crohns Colitis. 2021 Oct 12. pii: 6390023. doi: 10.1093.
    >> Share

  504. ELFIKY AMI, Ghiboub M, Li Yim AYF, Hageman IL, et al
    Carboxylesterase-1 assisted targeting of HDAC inhibitors to mononuclear myeloid cells in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Oct 11. pii: 6387695. doi: 10.1093.
    >> Share

  505. WALENTYNOWICZ M, van de Pavert I, Fierens L, Coenen S, et al
    Inflammatory Bowel Disease-related Behaviours [IBD-Bx] questionnaire: Development, validation, and prospective associations with fatigue.
    J Crohns Colitis. 2021 Oct 8. pii: 6383644. doi: 10.1093.
    >> Share

  506. JOJART B, Molnar T, Szabo V, Varga A, et al
    Erratum to: P459 Expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Oct 7. pii: 6383122. doi: 10.1093.
    >> Share

  507. ADAMINA M, Fiorino G
    At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery.
    J Crohns Colitis. 2021;15:1778-1779.
    >> Share

  508. MEKORI-DOMACHEVSKY E, Ben-Horin S
    Holistic approach to IBD patients.
    J Crohns Colitis. 2021;15:1782.
    >> Share

  509. SOOP M, Hancock L, Davies J
    Anti-TNF Therapy Before Intestinal Surgery for Crohn's Disease and the Risks of Postoperative Complications.
    J Crohns Colitis. 2021;15:1777.
    >> Share

  510. HONAP S, Irving PM, Kennedy NA
    Response to 'Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis'.
    J Crohns Colitis. 2021;15:1775-1776.
    >> Share

  511. RAINE T, Verstockt B, Kopylov U, Karmiris K, et al
    ECCO Topical Review: Refractory Inflammatory Bowel Disease.
    J Crohns Colitis. 2021;15:1605-1620.
    >> Share

  512. UNGAR B, Malickova K, Hanzel J, Abu Arisha M, et al
    Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
    J Crohns Colitis. 2021;15:1707-1719.
    >> Share

  513. VIEUJEAN S, Hu S, Bequet E, Salee C, et al
    Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis.
    J Crohns Colitis. 2021;15:1737-1750.
    >> Share

  514. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
    J Crohns Colitis. 2021;15:1649-1657.
    >> Share

  515. ILVEMARK JFKF, Hansen T, Goodsall TM, Seidelin JB, et al
    Defining transabdominal Intestinal Ultrasound treatment response and remission in Inflammatory Bowel Disease: Systematic review and expert consensus statement.
    J Crohns Colitis. 2021 Oct 6. pii: 6382324. doi: 10.1093.
    >> Share

  516. AARDOOM MA, Klomberg RCW, Kemos P, Ruemmele FM, et al
    The incidence and characteristics of venous thromboembolisms in paediatric-onset inflammatory bowel disease; a prospective international cohort study based on the PIBD-SETQuality Safety Registry.
    J Crohns Colitis. 2021 Oct 2. pii: 6380289. doi: 10.1093.
    >> Share

    September 2021
  517. RICCIUTO A, Lamb CA, Benchimol EI, Walker GJ, et al
    Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients.
    J Crohns Colitis. 2021 Sep 27. pii: 6376474. doi: 10.1093.
    >> Share

  518. DART RJ, Ellul P, Scharl M, Lamb CA, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions.
    J Crohns Colitis. 2021;15:1407-1409.
    >> Share

  519. FIOCCHI C, Dragoni G, Iliopoulos D, Katsanos K, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How.
    J Crohns Colitis. 2021;15:1410-1430.
    >> Share

  520. VERSTOCKT B, Noor NM, Marigorta UM, Pavlidis P, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.
    J Crohns Colitis. 2021;15:1431-1442.
    >> Share

  521. LI Y, Zhu L, Chen P, Wang Y, et al
    MALAT1 Maintains the Intestinal Mucosal Homeostasis in Crohn's Disease via the miR-146b-5p-CLDN11/NUMB Pathway.
    J Crohns Colitis. 2021;15:1542-1557.
    >> Share

  522. DE KRIJGER M, Wildenberg ME, Mookhoek A, Verheul S, et al
    Expression of MAdCAM-1 and Gut-homing T Cells in Inflamed Pouch Mucosa.
    J Crohns Colitis. 2021;15:1491-1499.
    >> Share

  523. RUSSO E, Giudici F, Ricci F, Scaringi S, et al
    Diving into Inflammation: A Pilot Study Exploring the Dynamics of the Immune-Microbiota Axis in Ileal Tissue Layers of Patients with Crohn's Disease.
    J Crohns Colitis. 2021;15:1500-1516.
    >> Share

  524. SOLA TAPIAS N, Denadai-Souza A, Rolland-Fourcade C, Quaranta-Nicaise M, et al
    Colitis Linked to Endoplasmic Reticulum Stress Induces Trypsin Activity Affecting Epithelial Functions.
    J Crohns Colitis. 2021;15:1528-1541.
    >> Share

  525. CHEN D, Fulmer C, Gordon IO, Syed S, et al
    Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know.
    J Crohns Colitis. 2021 Sep 24. pii: 6374854. doi: 10.1093.
    >> Share

  526. WONG D, Travis SPL
    Patient-reported Goals in Inflammatory Bowel Disease: What's the Problem?
    J Crohns Colitis. 2021 Sep 21. pii: 6373333. doi: 10.1093.
    >> Share

  527. SARBAGILI SHABAT C, Scaldaferri F, Zittan E, Hirsch A, et al
    Use of Fecal transplantation with a novel diet for mild to moderate active ulcerative colitis: The CRAFT UC randomized controlled trial.
    J Crohns Colitis. 2021 Sep 13. pii: 6369227. doi: 10.1093.
    >> Share

  528. PHILLIPS F, Verstockt B, Ribaldone DG, Guerra I, et al
    Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER case series.
    J Crohns Colitis. 2021 Sep 11. pii: 6368841. doi: 10.1093.
    >> Share

  529. KIM GH, Lee YC, Kim TJ, Kim ER, et al
    Risk of neurodegenerative diseases in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    J Crohns Colitis. 2021 Sep 9. pii: 6367800. doi: 10.1093.
    >> Share

  530. BOURGONJE AR, Hu S, Spekhorst LM, Zhernakova DV, et al
    The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Sep 7. pii: 6365883. doi: 10.1093.
    >> Share

    August 2021
  531. BOTS S, Nylund K, Gecse K
    Response to letter to the editor "Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index".
    J Crohns Colitis. 2021 Aug 14. pii: 6352305. doi: 10.1093.
    >> Share

  532. CARON B, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.
    J Crohns Colitis. 2021 Aug 14. pii: 6352195. doi: 10.1093.
    >> Share

  533. REUKEN PA, Andreas N, Grunert PC, Glockner S, et al
    T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease.
    J Crohns Colitis. 2021 Aug 11. pii: 6348138. doi: 10.1093.
    >> Share

  534. CROWLEY E, Ma C, Andic M, Feagan BG, et al
    Impact of Drug Approval Pathways for Paediatric Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Aug 11. pii: 6348023. doi: 10.1093.
    >> Share

  535. TSE CS, Van Citters AD, Ricci B, Freundlich NZ, et al
    Identifying and Predicting the Goals and Concerns Prioritized by Individuals with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Aug 5. pii: 6341120. doi: 10.1093.
    >> Share

  536. CARVELLO M, Bellato V, Maroli A, Hart A, et al
    A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high rate of restorative minimally invasive surgery.
    J Crohns Colitis. 2021 Aug 4. pii: 6338719. doi: 10.1093.
    >> Share

  537. PROIETTI E, Fuhler GM, Peppelenbosch MP
    Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD: Cause or Consequence?
    J Crohns Colitis. 2021;15:1247-1249.
    >> Share

  538. WELLENS J, Colombel JF, Satsangi JJ, Wong SY, et al
    SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
    J Crohns Colitis. 2021;15:1376-1386.
    >> Share

  539. LOCHHEAD P, Khalili H, Sachs MC, Chan AT, et al
    Statin Use and Risk of Inflammatory Bowel Diseases: Authors' Reply.
    J Crohns Colitis. 2021;15:1403-1404.
    >> Share

  540. TURSI A, Mocci G, Maconi G
    Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease.
    J Crohns Colitis. 2021;15:1399-1400.
    >> Share

  541. CARON B, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future.
    J Crohns Colitis. 2021;15:1387-1398.
    >> Share

  542. ELLRICHMANN M, Bethge J, Boesenkoetter J, Conrad C, et al
    Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy.
    J Crohns Colitis. 2021;15:1339-1345.
    >> Share

  543. CAER C, Gorreja F, Forsskahl SK, Brynjolfsson SF, et al
    TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn's Disease Patients.
    J Crohns Colitis. 2021;15:1346-1361.
    >> Share

  544. CAMBI MPC, Yamamoto T, Kotze PG
    Importance of Nutrition and Hypoalbuminaemia in Postoperative Morbidity in Crohn's Disease: Thinking Outside of the Box on Biologics as Single Risk Factors.
    J Crohns Colitis. 2021;15:1401-1402.
    >> Share

  545. CHANG I, Park S, Lee HJ, Kim I, et al
    Interpretation of XIAP Variants of Uncertain Significance in Paediatric Patients with Refractory Crohn's Disease.
    J Crohns Colitis. 2021;15:1291-1304.
    >> Share

  546. PETERS V, Spooren CEGM, Pierik MJ, Weersma RK, et al
    Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients.
    J Crohns Colitis. 2021;15:1305-1315.
    >> Share

    July 2021
  547. SEDANO R, Hogan M, Nguyen TM, Chang J, et al
    Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
    J Crohns Colitis. 2021 Jul 26. pii: 6328606. doi: 10.1093.
    >> Share

  548. PARK SH, Im JP, Park H, Jeong SK, et al
    Clinical features and long-term outcomes of pediatric-onset inflammatory bowel disease in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
    J Crohns Colitis. 2021 Jul 26. pii: 6328476. doi: 10.1093.
    >> Share

  549. BOSSUYT P, Pouillon L, Claeys S, D'Haens S, et al
    Ultra-proactive therapeutic drug monitoring of infliximab based on point-of-care-testing in inflammatory bowel disease: results of a pragmatic trial.
    J Crohns Colitis. 2021 Jul 23. pii: 6326544. doi: 10.1093.
    >> Share

  550. CHEE D, Nice R, Hamilton B, Jones E, et al
    Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease.
    J Crohns Colitis. 2021 Jul 21. pii: 6325142. doi: 10.1093.
    >> Share

  551. DIEZ-OBRERO V, Moratalla-Navarro F, Ibanez-Sanz G, Guardiola J, et al
    Transcriptome-wide association study for inflammatory bowel disease reveals novel candidate susceptibility genes in specific colon subsites and tissue categories.
    J Crohns Colitis. 2021 Jul 21. pii: 6324884. doi: 10.1093.
    >> Share

  552. ZITTAN E, Steinhart AH, Aran H, Milgrom R, et al
    The Toronto Ibd Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients.
    J Crohns Colitis. 2021 Jul 17. pii: 6323260. doi: 10.1093.
    >> Share

  553. DINALLO V, Di Fusco D, Di Grazia A, Laudisi F, et al
    The deubiquitinating enzyme OTUD5 sustains inflammatory cytokine response in inflammatory bowel disease.
    J Crohns Colitis. 2021 Jul 7. pii: 6316763. doi: 10.1093.
    >> Share

  554. CHOI WT, Salomao M, Zhao L, Alpert L, et al
    Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
    J Crohns Colitis. 2021 Jul 7. pii: 6316756. doi: 10.1093.
    >> Share

  555. DELISLE M, Wilkens R, Novak KL
    Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index.
    J Crohns Colitis. 2021 Jul 5. pii: 6315708. doi: 10.1093.
    >> Share

  556. RESTELLINI S, Lakatos PL
    Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle.
    J Crohns Colitis. 2021;15:1085-1086.
    >> Share

  557. GUPTA V, Mohsen W, Chapman TP, Satsangi J, et al
    Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021.
    J Crohns Colitis. 2021;15:1211-1221.
    >> Share

  558. DAI C, Jiang M, Huang YH
    Association Between Statin Use and Inflammatory Bowel Diseases.
    J Crohns Colitis. 2021;15:1246.
    >> Share

  559. ADAMINA M, Feakins R, Iacucci M, Spinelli A, et al
    ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology.
    J Crohns Colitis. 2021;15:1089-1105.
    >> Share

  560. XU M, Shen Y, Cen M, Zhu Y, et al
    Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice.
    J Crohns Colitis. 2021;15:1197-1210.
    >> Share

  561. LI XH, Feng ST, Cao QH, Coffey JC, et al
    Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn's Disease: A Potentially Novel Mesenteric Creeping Fat Index.
    J Crohns Colitis. 2021;15:1161-1173.
    >> Share

  562. KIM PH, Kim SH, Cho YA, Yoon HM, et al
    Ability of Pelvic Magnetic Resonance Imaging to Predict Clinical Course of Perianal Fistula in Paediatric Crohn's Disease Patients.
    J Crohns Colitis. 2021;15:1152-1160.
    >> Share

  563. SHAH RS, Bachour S, Jia X, Holubar SD, et al
    Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
    J Crohns Colitis. 2021;15:1142-1151.
    >> Share

  564. POLETTI M, Arnauts K, Ferrante M, Korcsmaros T, et al
    Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD.
    J Crohns Colitis. 2021;15:1222-1235.
    >> Share

  565. WONG ECL, Buffone E, Lee SJ, Dulai PS, et al
    End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
    J Crohns Colitis. 2021;15:1114-1119.
    >> Share

  566. COX SR, Clarke H, O'Keeffe M, Dubois P, et al
    Nutrient, fibre and FODMAP intakes and food-related quality of life in patients with inflammatory bowel disease and their relationship with gastrointestinal symptoms of differing aetiologies.
    J Crohns Colitis. 2021 Jul 3. pii: 6314229. doi: 10.1093.
    >> Share

    June 2021
  567. WATANABE S, Hibiya S, Katsukura N, Kitagawa S, et al
    Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells.
    J Crohns Colitis. 2021 Jun 28. pii: 6310549. doi: 10.1093.
    >> Share

  568. GUBATAN J, Rubin SJS, Bai L, Haileselassie Y, et al
    Vitamin D is Associated with alpha4beta7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Jun 28. pii: 6310486. doi: 10.1093.
    >> Share

  569. KUENZIG ME, Bitton A, Carroll MW, Kaplan GG, et al
    Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study.
    J Crohns Colitis. 2021 Jun 27. pii: 6310166. doi: 10.1093.
    >> Share

  570. KIM PH, Yoon HM, Jung AY, Lee JS, et al
    Diagnostic Performance of Diffusion-weighted Imaging for Evaluation of Bowel Inflammation in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308099. doi: 10.1093.
    >> Share

  571. GILMORE R, Hilley P, Srinivasan A, Choy M, et al
    Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.
    J Crohns Colitis. 2021 Jun 22. pii: 6308093. doi: 10.1093.
    >> Share

  572. ABAKKOUY Y, Cleynen I
    The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes.
    J Crohns Colitis. 2021;15:877-878.
    >> Share

  573. ATTAUABI M, Seidelin JB, Burisch J
    Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'.
    J Crohns Colitis. 2021;15:1080.
    >> Share

  574. STOCKER D, King MJ, El Homsi M, Carbonell G, et al
    Luminal Narrowing Alone Allows an Accurate Diagnosis of Crohn's Disease Small Bowel Strictures at Cross-Sectional Imaging.
    J Crohns Colitis. 2021;15:1009-1018.
    >> Share

  575. BUISSON A, Filippi J, Amiot A, Cadiot G, et al
    Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID.
    J Crohns Colitis. 2021;15:1000-1008.
    >> Share

  576. SYAL G, Shemtov R, Bonthala N, Vasiliauskas EA, et al
    Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.
    J Crohns Colitis. 2021;15:960-968.
    >> Share

  577. GIANOTTI RJ, Cheifetz AS
    Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?
    J Crohns Colitis. 2021 Jun 17. pii: 6301791. doi: 10.1093.
    >> Share

  578. JOHNSON AM, Harmsen WS, Aniwan S, Tremaine WJ, et al
    Prevalence and Impact of Obesity on Disease-Specific Outcomes in a Population-Based Cohort of Patients with Ulcerative Colitis.
    J Crohns Colitis. 2021 Jun 12. pii: 6297429. doi: 10.1093.
    >> Share

  579. PORTER RJ, Arends MJ, Churchhouse AMD, Din S, et al
    Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines.
    J Crohns Colitis. 2021 Jun 10. pii: 6295922. doi: 10.1093.
    >> Share

  580. GHOSH S, Sanchez Gonzalez Y, Zhou W, Clark R, et al
    Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
    J Crohns Colitis. 2021 Jun 9. pii: 6295522. doi: 10.1093.
    >> Share

  581. HERNANDEZ-ROCHA C, Borowski K, Turpin W, Filice M, et al
    Integrative analysis of colonic biopsies from inflammatory bowel disease patients identifies an interaction between microbial bile-acid inducible gene abundance and human Angiopoietin-like 4 gene expression.
    J Crohns Colitis. 2021 Jun 2. pii: 6291049. doi: 10.1093.
    >> Share

    May 2021
  582. FUMERY M, Chatelain D
    Histological Scores in Inflammatory Bowel Disease: A New Kid in the Block.
    J Crohns Colitis. 2021 May 27. pii: 6286012. doi: 10.1093.
    >> Share

  583. DHERI AK, Kuenzig ME, Mack DR, Murthy SK, et al
    Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada.
    J Crohns Colitis. 2021 May 21. pii: 6279878. doi: 10.1093.
    >> Share

  584. WEISSMAN S, Patel K, Kolli S, Lipcsey M, et al
    Obesity in Inflammatory Bowel Disease is Associated with Early Readmissions characterized by an Increased Systems and Patient-level Burden.
    J Crohns Colitis. 2021 May 17. pii: 6276891. doi: 10.1093.
    >> Share

  585. REZAZADEH ARDABILI A, Creemers RH, van Bodegraven AA
    COVID-19 in the IBD Population: The Need for Correct Nomenclature.
    J Crohns Colitis. 2021;15:872-873.
    >> Share

  586. BERTE' R, Mazza S, Stefanucci MR, Noviello D, et al
    Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
    J Crohns Colitis. 2021;15:864-868.
    >> Share

  587. REZAZADEH ARDABILI A, Hendrix EMB, Pierik MJ
    Remote Monitoring of Inflammatory Bowel Disease: What Kind of Patient-Reported Questionnaires Should We Use?
    J Crohns Colitis. 2021;15:869-870.
    >> Share

  588. CROSBY S, Schuh MJ, Farraye FA
    Rechallenge with Subcutaneous Ustekinumab After Hypersensitivity Reaction to Intravenous Ustekinumab.
    J Crohns Colitis. 2021;15:871.
    >> Share

  589. ASHTON JJ, Boukas K, Davies J, Stafford IS, et al
    Ileal Transcriptomic Analysis in Paediatric Crohn's Disease Reveals IL17- and NOD-signalling Expression Signatures in Treatment-naive Patients and Identifies Epithelial Cells Driving Differentially Expressed Genes.
    J Crohns Colitis. 2021;15:774-786.
    >> Share

  590. LOCHHEAD P, Khalili H, Sachs MC, Chan AT, et al
    Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study.
    J Crohns Colitis. 2021;15:757-765.
    >> Share

  591. KLANG E, Grinman A, Soffer S, Margalit Yehuda R, et al
    Automated Detection of Crohn's Disease Intestinal Strictures on Capsule Endoscopy Images Using Deep Neural Networks.
    J Crohns Colitis. 2021;15:749-756.
    >> Share

  592. MOTTA JP, Palese S, Giorgio C, Chapman K, et al
    Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation.
    J Crohns Colitis. 2021;15:787-799.
    >> Share

  593. NELSON A, Stewart CJ, Kennedy NA, Lodge JK, et al
    The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation.
    J Crohns Colitis. 2021;15:800-812.
    >> Share

  594. MULLER M, D'Amico F, Bonovas S, Danese S, et al
    TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2021;15:840-859.
    >> Share

    April 2021
  595. VAN ERP LW, van Gerven J, Bloem S, Groenen MJM, et al
    Acceptance and perceived control are independently associated with quality of life in inflammatory bowel disease: Introduction of a new segmentation model.
    J Crohns Colitis. 2021 Apr 28. pii: 6257076. doi: 10.1093.
    >> Share

  596. STRAATMIJER T, Biemans VBC, Hoentjen F, de Boer NKH, et al
    Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
    J Crohns Colitis. 2021 Apr 28. pii: 6256992. doi: 10.1093.
    >> Share

  597. OUAHED J, Kelsen JR, Spessott WA, Kooshesh K, et al
    Variants in STXBP3 Are Associated With Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation.
    J Crohns Colitis. 2021 Apr 23. pii: 6247960. doi: 10.1093.
    >> Share

  598. SLEIMAN J, Hitawala AA, Cohen B, Falloon K, et al
    Systematic review: Sweet syndrome associated with inflammatory bowel disease.
    J Crohns Colitis. 2021 Apr 23. pii: 6247949. doi: 10.1093.
    >> Share

  599. UNTERWEGER AL, Jensen MO, Giordanetto F, Jogini V, et al
    Suppressing Kv1.3 Ion Channel Activity with a Novel Small Molecule Inhibitor Ameliorates Inflammation in a Humanized Mouse Model of Ulcerative Colitis.
    J Crohns Colitis. 2021 Apr 23. pii: 6247959. doi: 10.1093.
    >> Share

  600. PANES J, Vermeire S, Dubinsky MC, Loftus EV, et al
    Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.
    J Crohns Colitis. 2021 Apr 22. pii: 6245086. doi: 10.1093.
    >> Share

  601. CHAPARRO M, Garre A, Iborra M, Sierra M, et al
    Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
    J Crohns Colitis. 2021 Apr 16. pii: 6228235. doi: 10.1093.
    >> Share

  602. JUNG S, Ye BD, Lee HS, Baek J, et al
    Identification of three novel susceptibility loci for inflammatory bowel disease in Koreans in an extended genome-wide association study.
    J Crohns Colitis. 2021 Apr 14. pii: 6225940. doi: 10.1093.
    >> Share

  603. FUMERY M, Yzet C, Chatelain D, Yzet T, et al
    Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management.
    J Crohns Colitis. 2021 Apr 12. pii: 6222697. doi: 10.1093.
    >> Share

  604. ATTAR A, Branche J, Coron E, Privat J, et al
    An Anti-migration Self-expandable and Removable Metal Stent for Crohn's Disease Strictures: A Nationwide Study From GETAID and SFED.
    J Crohns Colitis. 2021;15:521-528.
    >> Share

  605. NOVAK KL, Nylund K, Maaser C, Petersen F, et al
    Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease.
    J Crohns Colitis. 2021;15:609-616.
    >> Share

  606. ZHAO J, Wang H, Zhou J, Qian J, et al
    miR-130a-3p, a Preclinical Therapeutic Target for Crohn's Disease.
    J Crohns Colitis. 2021;15:647-664.
    >> Share

  607. DE VRIES LCS, Ghiboub M, van Hamersveld PHP, Welting O, et al
    Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis.
    J Crohns Colitis. 2021;15:617-630.
    >> Share

  608. CON D, Parthasarathy N, Bishara M, Luber RP, et al
    Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease.
    J Crohns Colitis. 2021;15:583-593.
    >> Share

  609. HUGOT JP, Dumay A, Barreau F, Meinzer U, et al
    Crohn's Disease: Is the Cold Chain Hypothesis Still Hot?
    J Crohns Colitis. 2021;15:678-686.
    >> Share

  610. LUND K, Larsen MD, Knudsen T, Kjeldsen J, et al
    Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study.
    J Crohns Colitis. 2021;15:575-582.
    >> Share

  611. VERSTOCKT B, Pouillon L, Bossuyt P
    Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath.
    J Crohns Colitis. 2021;15:692-693.
    >> Share

  612. RUTKA M, Pigniczki D, Molnar T
    Tofacitinib Therapy, the Lender of Last Resort.
    J Crohns Colitis. 2021;15:694.
    >> Share

  613. D'AMICO F, Guillo L, Baumann C, Danese S, et al
    Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis.
    J Crohns Colitis. 2021 Apr 5. pii: 6211061. doi: 10.1093.
    >> Share

  614. NG A
    Clinical efficacy of tofacitinib in moderate to severe ulcerative colitis.
    J Crohns Colitis. 2021 Apr 5. pii: 6211060. doi: 10.1093.
    >> Share

    March 2021
  615. BRESSLER B, Yarur A, Silverberg MS, Bassel M, et al
    Vedolizumab and Anti-TNFalpha Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
    J Crohns Colitis. 2021 Mar 31. pii: 6205394. doi: 10.1093.
    >> Share

  616. LANG-SCHWARZ C, Angeloni M, Agaimy A, Atreya R, et al
    Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn s disease.
    J Crohns Colitis. 2021 Mar 27. pii: 6196021. doi: 10.1093.
    >> Share

  617. PALMIERI C, Muller G, Kroesen AJ, Galata C, et al
    Perianal fistula-associated carcinoma in Crohn s disease: a multicenter retrospective case control study.
    J Crohns Colitis. 2021 Mar 27. pii: 6189787. doi: 10.1093.
    >> Share

  618. NORSA L, Berni Canani R, Duclaux-Loras R, Bequet E, et al
    Inflammatory bowel disease in patients with congenital chloride diarrhoea.
    J Crohns Colitis. 2021 Mar 26. pii: 6189668. doi: 10.1093.
    >> Share

  619. RUDDY J, Taft T, Keszthelyi D
    Gut-Brain Interactions in patients with Inflammatory Bowel Disease (IBD) and the role of Hypnotherapy in Managing Symptoms.
    J Crohns Colitis. 2021 Mar 18. pii: 6175701. doi: 10.1093.
    >> Share

  620. TORRES J, Halfvarson J, Rodriguez-Lago I, Hedin CRH, et al
    Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease.
    J Crohns Colitis. 2021 Mar 17. pii: 6175312. doi: 10.1093.
    >> Share

  621. KUCHARZIK T, Ellul P, Greuter T, Rahier JF, et al
    ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Mar 17. pii: 6175313. doi: 10.1093.
    >> Share

  622. PIOVANI D, Pansieri C, Kotha SRR, Piazza AC, et al
    Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2021 Mar 15. pii: 6171987. doi: 10.1093.
    >> Share

  623. VERSTOCKT B, Verstockt S, Abdu Rahiman S, Ke BJ, et al
    Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.
    J Crohns Colitis. 2021;15:485-498.
    >> Share

  624. COLLARD MK, Benoist S, Maggiori L, Zerbib P, et al
    A Reappraisal of Outcome of Elective Surgery After Successful Non-Operative Management of an Intra-Abdominal Abscess Complicating Ileocolonic Crohn's Disease: A Subgroup Analysis of a Nationwide Prospective Cohort.
    J Crohns Colitis. 2021;15:409-418.
    >> Share

  625. RICCIUTO A, Mack DR, Huynh HQ, Jacobson K, et al
    Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn's Disease.
    J Crohns Colitis. 2021;15:419-431.
    >> Share

  626. MOREAU J, Hammoudi N, Marthey L, Trang-Poisson C, et al
    Impact of an Education Programme on IBD Patients' Skills: Results of a Randomised Controlled Multicentre Study [ECIPE].
    J Crohns Colitis. 2021;15:432-440.
    >> Share

  627. NARULA N, Wong ECL, Dulai PS, Marshall JK, et al
    Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
    J Crohns Colitis. 2021;15:462-470.
    >> Share

  628. BARELLO S, Guida E, Bonanomi A, Menichetti J, et al
    WE-CARE IBD SCORE: Assessing High-quality Care From the Perspective of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2021;15:349-357.
    >> Share

  629. WINTJENS D, Bergey F, Saccenti E, Jeuring S, et al
    Disease Activity Patterns of Crohn's Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort.
    J Crohns Colitis. 2021;15:391-400.
    >> Share

  630. FOURIE S, Norton C, Jackson D, Czuber-Dochan W, et al
    'These discussions aren't happening'. Experiences of people living with inflammatory bowel disease talking about sexual well-being with healthcare professionals.
    J Crohns Colitis. 2021 Mar 4. pii: 6158978. doi: 10.1093.
    >> Share

  631. PAI RK, Hartman DJ, Leighton JA, Shabana PF, et al
    Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis.
    J Crohns Colitis. 2021 Mar 4. pii: 6158975. doi: 10.1093.
    >> Share

  632. ATREYA R, Neurath MF
    Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients?
    J Crohns Colitis. 2021 Mar 2. pii: 6156783. doi: 10.1093.
    >> Share

    February 2021
  633. LUDVIGSSON JF, Olen O, Larsson H, Halfvarson J, et al
    Association between inflammatory bowel disease and psychiatric morbidity and suicide: A Swedish nationwide population-based cohort study with sibling comparisons.
    J Crohns Colitis. 2021 Feb 26. pii: 6153473. doi: 10.1093.
    >> Share

  634. GUILLO L, Peyrin-Biroulet L, Louis E
    Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
    J Crohns Colitis. 2021 Feb 23. pii: 6146725. doi: 10.1093.
    >> Share

  635. ALLIN KH, Jacobsen RK, Ungaro RC, Colombel JF, et al
    Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study.
    J Crohns Colitis. 2021 Feb 20. pii: 6145790. doi: 10.1093.
    >> Share

  636. GOETGEBUER RL, Kreijne JE, Aitken CA, Dijkstra G, et al
    Increased risk of high-grade cervical neoplasia in women with inflammatory bowel disease: a case-controlled cohort study.
    J Crohns Colitis. 2021 Feb 20. pii: 6145789. doi: 10.1093.
    >> Share

  637. REINISCH W, Sandborn WJ, Danese S, Hebuterne X, et al
    Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II.
    J Crohns Colitis. 2021 Feb 18. pii: 6144575. doi: 10.1093.
    >> Share

  638. ARAKI T, Mitsuyama K, Yamasaki H, Morita M, et al
    Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease.
    J Crohns Colitis. 2021 Feb 17. pii: 6141509. doi: 10.1093.
    >> Share

  639. ACKERMANN M, Mucci A, McCabe A, Frei S, et al
    Restored macrophage function ameliorates disease pathophysiology in a mouse model for IL10 receptor deficient very early onset inflammatory bowel disease.
    J Crohns Colitis. 2021 Feb 17. pii: 6141466. doi: 10.1093.
    >> Share

  640. WATANABE S, Nishimura R, Shirasaki T, Katsukura N, et al
    Schlafen 11 is a novel target for mucosal regeneration in Ulcerative Colitis.
    J Crohns Colitis. 2021 Feb 17. pii: 6141476. doi: 10.1093.
    >> Share

  641. ZHAO M, Gonczi L, Lakatos PL, Burisch J, et al
    The burden of inflammatory bowel disease in Europe in 2020.
    J Crohns Colitis. 2021 Feb 14. pii: 6134782. doi: 10.1093.
    >> Share

  642. BARNES EL, Holubar SD, Herfarth HH
    Systematic Review and Meta-Analysis of Outcomes after Ileal Pouch-Anal Anastomosis in Primary Sclerosing Cholangitis-Ulcerative Colitis.
    J Crohns Colitis. 2021 Feb 5. pii: 6129144. doi: 10.1093.
    >> Share

  643. GHOSH S, Iacucci M
    Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement.
    J Crohns Colitis. 2021 Feb 5. pii: 6129099. doi: 10.1093.
    >> Share

    January 2021
  644. RUIGROK RAAA, Collij V, Sureda P, Klaassen MAY, et al
    The composition and metabolic potential of the human small intestinal microbiota within the context of inflammatory bowel disease.
    J Crohns Colitis. 2021 Jan 30. pii: 6123997. doi: 10.1093.
    >> Share

  645. GRIM C, Noble R, Uribe G, Khanipov K, et al
    Impairment of tissue resident mesenchymal stem cells in chronic ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2021 Jan 28. pii: 6121690. doi: 10.1093.
    >> Share

  646. ALLOCCA M, Bonovas S, Danese S
    Letter to the Editor Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.
    J Crohns Colitis. 2021 Jan 25. pii: 6119566. doi: 10.1093.
    >> Share

  647. LOVE BL, Finney CJ, Gaidos JKJ
    Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2021 Jan 25. pii: 6118663. doi: 10.1093.
    >> Share

  648. VERMEIRE S, Chiorean M, Panes J, Peyrin-Biroulet L, et al
    Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    J Crohns Colitis. 2021 Jan 21. pii: 6105062. doi: 10.1093.
    >> Share

  649. ZAIATZ BITTENCOURT V, Jones F, Tosetto M, Doherty GA, et al
    Dysregulation of metabolic pathways in circulating natural killer cells isolated from inflammatory bowel disease patients.
    J Crohns Colitis. 2021 Jan 18. pii: 6103919. doi: 10.1093.
    >> Share

  650. SANDBORN WJ, Feagan BG, Hanauer S, Vermeire S, et al
    Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study.
    J Crohns Colitis. 2021 Jan 13. pii: 6092404. doi: 10.1093.
    >> Share

  651. EFFENBERGER M, Reider S, Waschina S, Bronowski C, et al
    Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients.
    J Crohns Colitis. 2021;15:88-98.
    >> Share

  652. LEE S, Kuenzig ME, Ricciuto A, Zhang Z, et al
    Smoking May Reduce the Effectiveness of Anti-TNF Therapies to Induce Clinical Response and Remission in Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2021;15:74-87.
    >> Share

  653. THOMAS PWA, Ferwerda G, West RL, Hoentjen F, et al
    Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature.
    J Crohns Colitis. 2021;15:162-164.
    >> Share

  654. WEWER MD, Zhao M, Nordholm-Carstensen A, Weimers P, et al
    The Incidence and Disease Course of Perianal Crohn's Disease: A Danish Nationwide Cohort Study, 1997-2015.
    J Crohns Colitis. 2021;15:5-13.
    >> Share

  655. DE CAMPOS RJDS, Lucchetti G, Lucchetti ALG, Chebli LA, et al
    Influence of Religiousness and Spirituality on Remission Rate, Mental Health, and Quality of Life of Patients With Active Crohn's Disease: A Longitudinal 2-Year Follow-up Study.
    J Crohns Colitis. 2021;15:55-63.
    >> Share

  656. ZOLLNER A, Schmiderer A, Reider SJ, Oberhuber G, et al
    Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
    J Crohns Colitis. 2021;15:43-54.
    >> Share

  657. SAEVIK F, Eriksen R, Eide GE, Gilja OH, et al
    Development and Validation of a Simple Ultrasound Activity Score for Crohn's Disease.
    J Crohns Colitis. 2021;15:115-124.
    >> Share

  658. D'AMICO F, Nancey S, Danese S, Peyrin-Biroulet L, et al
    A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities.
    J Crohns Colitis. 2021;15:152-161.
    >> Share

  659. KUCHARZIK T, Maaser C, Maconi G
    A Simple Intestinal Ultrasound Score in Crohn's Disease: First Big Step Towards New Paradigms.
    J Crohns Colitis. 2021;15:3-4.
    >> Share

  660. MAASER C, Kucharzik T, Gecse K
    Is Intestinal Ultrasound Ready to be Used as Standard Monitoring Tool in Daily Practice and as Endpoint in Clinical Trials?
    J Crohns Colitis. 2021;15:1-2.
    >> Share

  661. DAI C, Jiang M, Huang YH
    Anti-Tubercular Therapy on the Long-Term Disease Course of Patients with Crohn's disease.
    J Crohns Colitis. 2021;15:169.
    >> Share

  662. BARBERIO B, Segal JP, Quraishi MN, Black CJ, et al
    Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    J Crohns Colitis. 2021 Jan 12. pii: 6089122. doi: 10.1093.
    >> Share

  663. DE VOOGD F, Wilkens R, Gecse K, Allocca M, et al
    A reliability study - strong inter-observer agreement of an expert panel for intestinal ultrasound in ulcerative colitis.
    J Crohns Colitis. 2021 Jan 9. pii: 6073674. doi: 10.1093.
    >> Share

  664. BOTS S, Nylund K, Lowenberg M, Gecse K, et al
    Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound index.
    J Crohns Colitis. 2021 Jan 7. pii: 6067606. doi: 10.1093.
    >> Share

    December 2020
  665. VAN DER SLOOT KWJ, Voskuil MD, Blokzijl T, Dinkla A, et al
    Isotype specific antibody responses to Mycobacterium Avium subspecies Paratuberculosis antigens are associated with the use of biological therapy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Dec 30. pii: 6055607. doi: 10.1093.
    >> Share

  666. GUILLO L, D'Amico F, Danese S, Peyrin-Biroulet L, et al
    Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
    J Crohns Colitis. 2020 Dec 24. pii: 6046385. doi: 10.1093.
    >> Share

  667. CROUWEL F, Waaijenberg-Warmenhoven P, Buiter HJC, de Boer NK, et al
    Recurrent COVID-19 in a patient with ulcerative colitis on vedolizumab therapy.
    J Crohns Colitis. 2020 Dec 22. pii: 6044002. doi: 10.1093.
    >> Share

  668. RAHMI G, Coron E, Perrod G, Levy M, et al
    Probe-based confocal laser endomicroscopy for in vivo assessment of histological healing in ulcerative colitis: development and validation of the ENHANCE index.
    J Crohns Colitis. 2020 Dec 18. pii: 6041240. doi: 10.1093.
    >> Share

  669. BANCIL AS, Sandall AM, Rossi M, Chassaing B, et al
    Food additive emulsifiers and their impact on gut microbiome, permeability and inflammation: mechanistic insights in inflammatory bowel disease.
    J Crohns Colitis. 2020 Dec 18. pii: 6041235. doi: 10.1093.
    >> Share

  670. VENTIN-HOLMBERG R, Eberl A, Saqib S, Korpela K, et al
    Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease.
    J Crohns Colitis. 2020 Dec 10. pii: 6029424. doi: 10.1093.
    >> Share

  671. VERMEIRE S, Su C, Lawendy N, Kobayashi T, et al
    Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomized RIVETING Trial.
    J Crohns Colitis. 2020 Dec 8. pii: 6027842. doi: 10.1093.
    >> Share

  672. MONSTAD IL, Solberg IC, Cvancarova M, Hovde O, et al
    Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study.
    J Crohns Colitis. 2020 Dec 2. pii: 6015889. doi: 10.1093.
    >> Share

    November 2020
  673. JOHNSON LE, Lee MJ, Turner-Moore T, Grinsted Tate LR, et al
    Systematic review of factors affecting transition readiness skills in patients with inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 30. pii: 6012510. doi: 10.1093.
    >> Share

  674. HAMAMA-RAZ Y, Nativ S, Hamama L
    Posttraumatic Growth in Inflammatory Bowel Disease Patients: The Role of Illness Cognitions and Physical Quality in Life.
    J Crohns Colitis. 2020 Nov 30. pii: 6012764. doi: 10.1093.
    >> Share

  675. TADBIRI S, Nachury M, Bouhnik Y, Serrero M, et al
    The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 27. pii: 6007776. doi: 10.1093.
    >> Share

  676. WINTHROP KL, Loftus EV Jr, Baumgart DC, Reinisch W, et al
    Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    J Crohns Colitis. 2020 Nov 27. pii: 6007683. doi: 10.1093.
    >> Share

  677. VAN DEN BERGHE N, Verstockt B, Gils A, Sabino J, et al
    Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations.
    J Crohns Colitis. 2020 Nov 27. pii: 6007493. doi: 10.1093.
    >> Share

  678. EVERHOV AH, Bruze G, Soderling J, Askling J, et al
    Women's earnings are more affected by inflammatory bowel disease than men's: a register-based Swedish cohort study.
    J Crohns Colitis. 2020 Nov 27. pii: 6007494. doi: 10.1093.
    >> Share

  679. HOEKMAN DR, Vlieger AM, Stokkers PC, Mahhmod N, et al
    Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial.
    J Crohns Colitis. 2020 Nov 27. pii: 6007495. doi: 10.1093.
    >> Share

  680. AGRAWAL M, Brenner EJ, Zhang X, Colombel JF, et al
    Physician practice patterns on holding inflammatory bowel disease medications due to COVID-19 in the SECURE-IBD registry.
    J Crohns Colitis. 2020 Nov 24. pii: 6000079. doi: 10.1093.
    >> Share

  681. TRAN-MINH ML, Gornet JM, Maillet M, Houze P, et al
    Safety of hydrocortisone premedication discontinuation in patients with inflammatory bowel disease on maintenance therapy with Infliximab: a prospective clinical and pharmacological study.
    J Crohns Colitis. 2020 Nov 18. pii: 5986749. doi: 10.1093.
    >> Share

  682. KALLA R, Adams AT, Bergemalm D, Vatn S, et al
    Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.
    J Crohns Colitis. 2020 Nov 17. pii: 5985635. doi: 10.1093.
    >> Share

  683. GALLAGHER K, Catesson A, Griffin JL, Holmes E, et al
    Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2020 Nov 11. pii: 5974408. doi: 10.1093.
    >> Share

  684. KIM MA, Kim YH, Chun J, Lee HS, et al
    The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2020 Nov 11. pii: 5974276. doi: 10.1093.
    >> Share

  685. BARBERIO B, Black CJ, Savarino EV, Ford AC, et al
    Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    J Crohns Colitis. 2020 Nov 11. pii: 5974124. doi: 10.1093.
    >> Share

  686. SEBASTIAN S, Gonzalez HA, Peyrin-Biroulet L
    Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease.
    J Crohns Colitis. 2020;14:1632-1643.
    >> Share

  687. TURSI A, Papa A
    Impact of Anti-TNFalpha Antibodies on the Risk of Covid-19 and its Severity in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:1646-1647.
    >> Share

  688. VOSKUIL MD, Spekhorst LM, van der Sloot KWJ, Jansen BH, et al
    Genetic risk scores identify genetic aetiology of inflammatory bowel disease phenotypes.
    J Crohns Colitis. 2020 Nov 6. pii: 5957220. doi: 10.1093.
    >> Share

  689. YOKOYAMA Y, Sawada K, Aoyama N, Yoshimura N, et al
    Erratum to: Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab.
    J Crohns Colitis. 2020 Nov 6. pii: 5958727. doi: 10.1093.
    >> Share

    October 2020
  690. MAHMOUD R, van Lieshout C, Frederix GWJ, Jharap B, et al
    Continuation of anti-TNF in patients with Ulcerative Colitis in Remission is not Cost-effective compared to Treatment Withdrawal: a Markov Model.
    J Crohns Colitis. 2020 Oct 30. pii: 5944009. doi: 10.1093.
    >> Share

  691. SIEGEL CA, Christensen B, Kornbluth A, Rosh JR, et al
    Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.
    J Crohns Colitis. 2020;14.
    >> Share

  692. LEWIN S, Lees C, Regueiro M, Hart A, et al
    International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14.
    >> Share

  693. DE LIMA-KARAGIANNIS A, Juillerat P, Sebastian S, Pedersen N, et al
    Management of Pregnant Inflammatory Bowel Disease Patients During the COVID-19 Pandemic.
    J Crohns Colitis. 2020;14.
    >> Share

  694. ABREU MT, Peyrin-Biroulet L
    Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2020;14.
    >> Share

  695. NG SC, Mak JWY, Hitz L, Chowers Y, et al
    COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal.
    J Crohns Colitis. 2020;14.
    >> Share

  696. DOTAN I, Panaccione R, Kaplan GG, O'Morain C, et al
    Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force.
    J Crohns Colitis. 2020;14.
    >> Share

  697. ALLEZ M, Fleshner P, Gearry R, Lakatos PL, et al
    Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.
    J Crohns Colitis. 2020;14.
    >> Share

  698. QURAISHI MN, Iqbal TH, Hart AL
    Precision Medicine with FMT for Ulcerative Colitis: Are We There Yet?
    J Crohns Colitis. 2020 Oct 20. pii: 5932516. doi: 10.1093.
    >> Share

  699. DERIKX LAAP, Lantinga MA, de Jong DJ, van Dop WA, et al
    Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    J Crohns Colitis. 2020 Oct 20. pii: 5932316. doi: 10.1093.
    >> Share

  700. BOSSUYT P, Bisschops R, Vermeire S, De Hertogh G, et al
    Variability in the distribution of histological disease activity in the colon of patients with ulcerative colitis.
    J Crohns Colitis. 2020 Oct 14. pii: 5923369. doi: 10.1093.
    >> Share

  701. ATTAUABI M, Poulsen A, Theede K, Pedersen N, et al
    Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease - A Danish prospective population-based cohort study.
    J Crohns Colitis. 2020 Oct 9. pii: 5920382. doi: 10.1093.
    >> Share

  702. ALOI M, Bramuzzo M, Norsa L, Arrigo S, et al
    Disease activity patterns in the first 5 years after diagnosis in children with ulcerative colitis: a population-based study.
    J Crohns Colitis. 2020 Oct 6. pii: 5918427. doi: 10.1093.
    >> Share

    September 2020
  703. MEREDITH J, Khedim CA, Henderson P, Wilson DC, et al
    Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in a patient receiving Infliximab therapy for Inflammatory Bowel Disease.
    J Crohns Colitis. 2020 Sep 30. pii: 5913452. doi: 10.1093.
    >> Share

  704. ARHI C, Askari A, Nachiappan S, Bottle A, et al
    Stage at diagnosis and survival of colorectal cancer with or without underlying inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2020 Sep 29. pii: 5912977. doi: 10.1093.
    >> Share

    June 2020
  705. D'AMICO F, Baumann C, Rousseau H, Danese S, et al
    Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist.
    J Crohns Colitis. 2020;14:710-718.
    >> Share

  706. SOMERS M, Bossuyt P, Ferrante M, Peeters H, et al
    Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2020;14:680-685.
    >> Share

  707. VON MARTELS JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, et al
    Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study].
    J Crohns Colitis. 2020;14:595-607.
    >> Share

  708. FAUNY M, D'Amico F, Bonovas S, Netter P, et al
    Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review.
    J Crohns Colitis. 2020;14:688-693.
    >> Share

  709. ZHOU C, Wu XR, Liu HS, Liu XH, et al
    Immunomodulatory Effect of Urine-derived Stem Cells on Inflammatory Bowel Diseases via Downregulating Th1/Th17 Immune Responses in a PGE2-dependent Manner.
    J Crohns Colitis. 2020;14:654-668.
    >> Share

  710. VALE RODRIGUES R, Sladek M, Katsanos K, van der Woude CJ, et al
    Diagnosis and Outcome of Oesophageal Crohn's Disease.
    J Crohns Colitis. 2020;14:624-629.
    >> Share

  711. AL NABHANI Z, Berrebi D, Martinez-Vinson C, Montcuquet N, et al
    Nod2 Protects the Gut From Experimental Colitis Spreading to Small Intestine.
    J Crohns Colitis. 2020;14:669-679.
    >> Share

  712. ZHAO M, Burisch J
    The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease.
    J Crohns Colitis. 2020;14:573-574.
    >> Share

  713. EDER P, Dobrowolska A, Rydzewska G
    Historical Upheavals and Eponyms in Crohn's Disease-Is There Any Relation?
    J Crohns Colitis. 2020;14:719.
    >> Share

    May 2020
  714. NEHRA AK, Sheedy SP, Wells ML, VanBuren WM, et al
    Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?
    J Crohns Colitis. 2020;14:455-464.
    >> Share

  715. DANIELOU M, Sarter H, Pariente B, Fumery M, et al
    Natural History of Perianal Fistulising Lesions in Patients With Elderly-onset Crohn's Disease: A Population-based Study.
    J Crohns Colitis. 2020;14:501-507.
    >> Share

  716. PILLAI N, Lupatsch JE, Dusheiko M, Schwenkglenks M, et al
    Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data.
    J Crohns Colitis. 2020;14:490-500.
    >> Share

  717. CONDAMINA M, Diaz E, Jamart C, Loget J, et al
    Severe Attack of Henoch-Schonlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn's Disease.
    J Crohns Colitis. 2020;14:538-542.
    >> Share

  718. SPARROW MP, Papamichael K, Ward MG, Riviere P, et al
    Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.
    J Crohns Colitis. 2020;14:542-556.
    >> Share

  719. RODRIGUEZ-LAGO I, Gisbert JP
    The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn's Disease.
    J Crohns Colitis. 2020;14:557-566.
    >> Share

  720. DHALIWAL J, Walters TD, Mack DR, Huynh HQ, et al
    Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network.
    J Crohns Colitis. 2020;14:445-454.
    >> Share

  721. MADARAME A, Kimura H, Kunisaki R
    Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
    J Crohns Colitis. 2020;14:569-570.
    >> Share

  722. CHATEAU T, Angioi K, Peyrin-Biroulet L
    Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.
    J Crohns Colitis. 2020;14:571.
    >> Share

    March 2020
  723. ANNESE V
    Small Bowel Adenocarcinoma in Crohn's Disease: An Underestimated Risk?
    J Crohns Colitis. 2020;14:285-286.
    >> Share

  724. CARBONNEL F, Svrcek M
    Progress in the Molecular and Histological Dissection of Crohn's Disease-associated Small Bowel Adenocarcinomas.
    J Crohns Colitis. 2020;14:283-284.
    >> Share

  725. DELATTRE C, Lewis A, Kirchgesner J, Nion-Larmurier I, et al
    Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes.
    J Crohns Colitis. 2020;14:342-350.
    >> Share

  726. FELWICK RK, Dingley GJR, Martinez-Nunez R, Sanchez-Elsner T, et al
    MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier.
    J Crohns Colitis. 2020;14:381-392.
    >> Share

  727. FIELDS AC, Hu FY, Lu P, Irani J, et al
    Small Bowel Adenocarcinoma: Is There a Difference in Survival for Crohn's Versus Sporadic Cases?
    J Crohns Colitis. 2020;14:303-308.
    >> Share

  728. BORREN NZ, Tan W, Colizzo FP, Luther J, et al
    Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
    J Crohns Colitis. 2020;14:309-315.
    >> Share

  729. PIOVANI D, Danese S, Peyrin-Biroulet L, Bonovas S, et al
    Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study.
    J Crohns Colitis. 2020;14:323-331.
    >> Share

  730. FRANZE E, Monteleone I, Laudisi F, Rizzo A, et al
    Cadherin-11 Is a Regulator of Intestinal Fibrosis.
    J Crohns Colitis. 2020;14:406-417.
    >> Share

  731. VERSTOCKT B, Mertens E, Dreesen E, Outtier A, et al
    Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naive and Anti-TNF Exposed IBD Patients.
    J Crohns Colitis. 2020;14:332-341.
    >> Share

  732. POREDSKA K, Kunovsky L, Marek F, Kala Z, et al
    The Influence of Microscopic Inflammation at Resection Margins on Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease.
    J Crohns Colitis. 2020;14:361-368.
    >> Share

  733. ARPA G, Grillo F, Giuffrida P, Nesi G, et al
    Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis.
    J Crohns Colitis. 2020;14:295-302.
    >> Share

  734. PELLINO G, Vinci D, Signoriello G, Kontovounisios C, et al
    Long-Term Bowel Function and Fate of the Ileal Pouch After Restorative Proctocolectomy in Patients With Crohn's Disease: A Systematic Review With Meta-Analysis and Metaregression.
    J Crohns Colitis. 2020;14:418-427.
    >> Share

  735. LIAO X, Li G, McBride R, Houldsworth J, et al
    Clinicopathological and Molecular Characterisation of Crohn's Disease-associated Small Bowel Adenocarcinomas.
    J Crohns Colitis. 2020;14:287-294.
    >> Share

    February 2020
  736. ADAMINA M, Bonovas S, Raine T, Spinelli A, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
    J Crohns Colitis. 2020;14:155-168.
    >> Share

  737. MAGRO F, Lopes J, Borralho P, Lopes S, et al
    Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels.
    J Crohns Colitis. 2020;14:169-175.
    >> Share

  738. WASMANN KA
    Complications While Waiting for IBD Surgery-Short Report.
    J Crohns Colitis. 2020;14:277-280.
    >> Share

  739. KEITA AV, Alkaissi LY, Holm EB, Heil SDS, et al
    Enhanced E. coli LF82 Translocation through the Follicle-associated Epithelium in Crohn's Disease is Dependent on Long Polar Fimbriae and CEACAM6 expression, and Increases Paracellular Permeability.
    J Crohns Colitis. 2020;14:216-229.
    >> Share

  740. AGRAWAL M, Burisch J, Colombel JF, C Shah S, et al
    Viewpoint: Inflammatory Bowel Diseases Among Immigrants From Low- to High-Incidence Countries: Opportunities and Considerations.
    J Crohns Colitis. 2020;14:267-273.
    >> Share

  741. PIERRE N, Salee C, Massot C, Bletard N, et al
    Proteomics Highlights Common and Distinct Pathophysiological Processes Associated with Ileal and Colonic Ulcers in Crohn's Disease.
    J Crohns Colitis. 2020;14:205-215.
    >> Share

  742. COSTA-MOREIRA P, Lopes S, Santos AL, Pedrosa AF, et al
    Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review.
    J Crohns Colitis. 2020;14:274-276.
    >> Share

    January 2020
  743. TORRES J, Bonovas S, Doherty G, Kucharzik T, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
    J Crohns Colitis. 2020;14:4-22.
    >> Share

  744. TRAVIS S
    IM-UNITI at Three Years: Stellar Stelara(R) or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
    J Crohns Colitis. 2020;14:1-3.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016